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1 Introduction 
1.1 Cancer gene therapy 
 
Cancer comprises more than 100 diseases with diverse phenotypes that ultimately lead to 
approximately 13% of all human deaths worldwide. Cancer, referred to as a malignant 
neoplasm, is characterized by uncontrolled and abnormal growth of cells. These cells are 
able to spread locally or through the bloodstream and lymphatic system to other parts of the 
body. In general, malignant cancers cause significant morbidity and are lethal to the host if 
not treated.  
Based on its complex biology, the field of cancer research has investigated numerous 
therapeutic approaches. One major field is gene therapy, which was first evaluated in 1972, 
and has become more and more popular over the last 20 years. Gene therapy consists of the 
introduction of genetic material into cells for a therapeutic purpose. The initial aim of the gene 
therapy field was the correction of inherited genetic diseases by providing to the targeted 
cells a functional copy of the deficient gene responsible for the disease (Touchefeu et al. 
2010). One central issue associated with gene therapy approaches is the method used for 
delivery of the therapy gene. Gene delivery can occur by two main classes of methods – viral 
and non-viral systems. The viral method makes use of recombinant viruses as gene delivery 
vehicles which bind to their host cells and specifically introduce their genetic material into 
these cells as part of their replication cycle. Most viral vector approaches have focused on 
adenovirus, adeno-associated virus, retrovirus, herpes simplex virus and pox virus. The 
major hurdles of effective oncolytic virotherapy, in particular after systemic application, have 
been antiviral immune responses, inefficient viral spread within the tumor and significant 
virus pooling in the liver, reducing the levels of viable virus reaching the tumor resulting in 
limited transduction efficiency (Cattaneo et al. 2008). 
Non-viral gene delivery systems include the use of DNA-complexes. The DNA carriers used 
include: oligonucleotides, liposomes, dendrimers and inorganic nanoparticles. These are all 
generally polycationic molecules that are able to build a stable complex with the negatively 
charged therapeutic nucleic acid based on electrostatic interaction to avoid enzymatic 
degradation by nucleases in the blood stream and destabilization by electrostatic interactions 
with serum proteins (Burke and Pun 2008). The surface of these complexes is often modified 
in a chemical or biological way for specific or active targeting.  
More recently the concept of stem cell driven therapy has been included in the field of non-
viral gene delivery methods. Stem cells have the intrinsic ability to “home” to growing tumors 
and are hypoimmunogenic. Therefore, they can be used as a “Trojan Horse” to deliver gene 
therapy deep into tumor environments. They can also serve as carriers for nanoparticles to 
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allow cell tracking and simultaneous cancer detection. This thesis focused on the potential 
use of engineered mesenchymal stem cells as therapy vehicles for the treatment of solid 
tumors.  
 
1.2 Tumor biology 
1.2.1 Role of tumor stroma in tumor biology 
 
The hallmarks of cancer constitute an organizing principle that provides a logical framework 
for understanding the remarkable diversity of neoplastic diseases. They include sustaining 
proliferative signaling, evading growth suppressors, resting cell death, enabling replicative 
immortality, inducing angiogenesis and activating invasion and metastasis (Hanahan and 
Weinberg 2000; 2011). But importantly, tumor cells are only able to exist within a complex 
tumor environment called tumor stroma. The tumor stroma is composed of various 
compartments and cell types including endothelial cells, pericytes, fibroblasts, infiltrating 
leukocytes, which are all embedded in an extensive extracellular matrix (ECM). Many of the 
characteristics of tumors detailed above are provided in part by interaction of the tumor 
stroma with the cancer cells.  
The most prominent cell type in the tumor stroma are cancer-associated fibroblasts (CAF). 
They belong to the tumor-associated mesenchymal stem cell types and have their origin from 
resident local fibroblasts or bone marrow-derived progenitor cells. Because of their different 
origins, CAFs show high heterogeneity in marker expression, but the expression of α-smooth 
muscle actin (α-SMA), platelet-derived growth factor (PDGF) receptor and fibroblast specific 
protein (FSP)-1 is found to overlap in most tumor types (Anderberg et al. 2009; Sugimoto et 
al. 2006). Tumor cells can be directly stimulated by CAFs via production of various growth 
factors [hepatocyte growth factors (HGF), epidermal growth factor (EGF)], hormones and 
cytokines [stromal-derived factor (SDF)-1α (CXCL12), interleukin-6 (IL6)] in a context-
dependent manner (Bhowmick et al. 2004; Engels et al. 2012; Olumi et al. 1999; Orimo et al. 
2005; Orimo and Weinberg 2006). CAFs can also stimulate tumor growth through production 
of insulin-like growth factor-1 and -2 that in turn stimulate proliferation and promote tumor cell 
survival. CAFs also express collagen A, which is essential for construction of the ECM, 
resulting in a stronger general structure of the stroma and resulting in a physical barrier for 
lymphocytes and macrophages, as well as chemotherapeutical reagents (Engels et al. 2012; 
Li et al. 2007). Stem and progenitor cells from the bone marrow are now seen as important 
factors in tumor progression in that they can act as a key source for tumor-associated 
stromal cells (Hanahan and Weinberg 2000; 2011). The progenitor cells migrate into the 
tumor and differentiate into various stromal cell types. 
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Figure 1 Schematic illustration of the tumor microenvironment in most solid tumors. The parenchyma 
and stroma of tumors contain distinct cell types and subtypes that collectively enable tumor growth 
and progression. The immune inflammatory cells present in tumors can include both tumor-promoting 
as well as tumor-killing subclasses (Hanahan and Weinberg 2011).  
 
 
Thus the tumor stroma is essential for tumor initiation, growth and progression. Angiogenesis 
is induced early during the development of invasive cancers and is a key factor in tumor 
growth, because the supply of oxygen and nutrients has to be ensured. The interaction 
between the tumor stroma and cancer cells stimulates the expression of proangiogenic 
factors including vascular endothelial growth factor (VEGF), CXCL12 and matrix-remodeling 
protein matrix metalloproteinases (MMP)-2 and MMP9, which are essential for blood vessel 
development. VEGF is involved in orchestrating new blood vessel growth during embryonic 
and postnatal development. In adults it is responsible for homeostatic survival of endothelial 
cells and is regulated by hypoxia as well as by oncogene signaling (Hanahan and Weinberg 
2000; 2011). The blood vessels produced within tumors are abnormal in their function and 
have a leaky structure, which allows molecules to freely traverse between the interstitial 
space and blood capillaries.  
The second important component for tumor progression is suppression of an immune 
response. The tumor tissue produces many chemokines like CCL2 and CSF1 which result in 
an immune response of the body (Mueller and Fusenig 2004). Especially tumor associated-
macrophages (TAM) play an important role in tumor progression. They exhibit some anti-
tumorigenic proteins, but also express growth factors like VEGF, HGF, PDGF, TGFβ, and 
cytokines such as TNFα and IL8. In contrast, TAM also secretes MMP2 and MMP9 resulting 
in a proangiogenic and prometastatic effect (Bhowmick and Moses 2005; Gao and Mittal 
2009; Mueller and Fusenig 2004). The invasion of lymphocytes, dendritic cells, neutrophils, 
eosinophils, mast cells and monocytes leads to enhanced tumor progression. 
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1.2.2 Role of chemokines in tumor development 
 
Chemokines are chemotactic cytokines that cause the directed migration of leukocytes and 
are induced by inflammatory cytokines and growth factors (Tanaka et al. 2005). Chemokine 
signaling results in transcription of target genes, which are involved in cell invasion, motility, 
interactions with the ECM and survival (Viola et al. 2012). Chemokines are responsible for 
the recruitment of immune cells to organize the anti-tumor or inflammatory response via a 
chemokine gradient (Balkwill 2004). Chemokines are also able to sustain tumor survival, 
promote progression and drive metastasis. For example, the chemokine CCL5, also called 
RANTES (regulated on activation, normal T-cell expressed and secreted), is normally 
involved in inflammation and is expressed by inflammatory tissue. In tumors, CCL5 has been 
shown to play an important role in tumor progression and invasion, and is also involved in the 
recruitment of tumor-associated macrophages (TAM) (Nelson et al. 1993; Von Luettichau et 
al. 1996). CCL5 expression is found in many tumor entities such as melanoma, prostate 
cancer, Hodgkin´s lymphoma and breast cancer (Fischer et al. 2003; Konig et al. 2004; 
Luboshits et al. 1999; Mrowietz et al. 1999). CCL5 signals through the chemokine receptors 
CCR1, CCR3 and CCR5 (Tanaka et al. 2005). 
A pro-malignant activity of CCL5 was identified in experimental breast cancer models. Soria 
et al. showed high expression of CCL5 and CCL2 in breast tumor cells at primary tumor sites 
as well as in metastases, whereas only minimal expression was found in normal breast 
epithelial cells. These data indicate that CCL2 and CCL5 expression is needed in the course 
of malignant transformation and suggest the important role of chemokines in breast cancer 
development and progression (Soria et al. 2012). Furthermore, in a murine pancreatic tumor 
model and a breast cancer mouse model inhibition of the CCR5 receptor resulted in a 
reduction of CCL5 production and thereby reduced growth of tumor and metastases 
(Stormes et al. 2005; Tan et al. 2009).  
Importantly for the focus of this thesis, CCL5 is not only expressed by tumor cells, Karnoub 
et al. have also shown an induction of CCL5 by mesenchymal stem cells in a breast cancer 
mouse model. Breast cancer cells were found to stimulate the de novo secretion of CCL5 
from mesenchymal stem cells, which then acts in a paracrine fashion on cancer cells to 
enhance their motility, invasion and metastasis (Karnoub et al. 2007).  
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1.3 Mesenchymal stem cells (MSC) 
1.3.1 Characterization of MSCs 
 
Stem cells have unlimited self-renewal capacity and are able to produce more differentiated 
progenitors (embryonic and adult stem cells). Bone marrow-derived stem cells are the best 
characterised and most accessible type of adult stem cells. They can be subdivided into 
haematopoietic stem cells that produce progenitors for all types of mature blood cells, and 
mesenchymal stem cells (MSC). The term “mesenchymal” as opposed to “epithelial” or 
“parenchymal” defines a progenitor cell with fusiform shape and able to actively move. MSCs 
are multipotent progenitors with the ability to differentiate into cells of mesenchymal tissue 
including bone cartilage, fat, tendon, muscle and marrow stroma (Pittenger 2008). They play 
an important role in retention and reconstruction of the tissue integrity in the course of normal 
cell turnover as well as in wound healing. They are easy to isolate from the bone marrow, the 
main source of MSCs (0.01% - 0.001%), but they can also be extracted from blood or fat 
(Korbling and Estrov 2003; Kumar et al. 2008).  
One major issue associated with MSCs is their identification as no specific marker or simple 
assay is currently available. The “International Society of Cellular Therapy” has defined the 
hallmarks of MSCs, which include their ability to adhere to plastic, a fibroblast-like 
morphology, and the ability to undergo differentiation toward chondrogenic, adipogenic and 
osteoplastic lineages. MSC should show positive staining for markers such as CD29, CD44, 
CD73, CD90, CD106, but they should be negative for markers of the hematopoietic lineage, 
including the lipopolysaccharide receptor CD14, CD34 and the leukocyte common antigen 
CD45 (Pittenger 2008). Furthermore, MSCs should express low levels of the major 
histocompatibility complex (MHC) I, and should lack expression of MHC II as well as the 
costimulatory molecules CD80, CD86 and CD40 (Kumar et al. 2008).  
MSCs play an important role in tissue repair based on their ability to differentiate into various 
cell types and through paracrine signalling, which generally lead to reduced inflammation, 
enhanced angiogenesis and the induction of cell migration and proliferation (Gnecchi et al. 
2008). They secrete many known mediators of tissue repair including growth factors, 
cytokines and chemokines, specifically VEGF, PDGF, HGF and TGF-β and thereby facilitate 
the recruitment of fibroblasts and host stem cells (Hocking and Gibran 2010). The potential of 
MSCs to differentiate into required cell types was shown by Conrad et al. in a murine 
lymphatic edema model resulting in the formation of lymphoendothelial cells for a functional 
lymphatic vasculature after systemic MSC injection (Conrad et al. 2009). 
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1.3.2 MSCs as gene transfer vehicles  
 
The following properties make MSCs ideal therapeutic cellular carriers: they are relatively 
easy to isolate and expand in vitro, they show easy handling for ex vivo genetic modification; 
autologous transplantation in patients is possible (overcome issues of host immune 
responses) and they also show hypoimmunogenicity (and are thus also suitable for allogenic 
transplantations) (Tang et al. 2010). The migration behaviour and distribution pattern of 
MSCs show clear differences in healthy versus tumor-bearing mice. After systemic injection 
in healthy mice MSCs are predominantly found in lung at an early stage and later in spleen 
as well as thymus, lymph nodes, skin, brain, salivary glands, intestine and sometimes also in 
the bone marrow (Pereira et al. 1998; Von Luttichau et al. 2005). After systemic injection into 
mice bearing solid tumors, MSCs show strong preferential migration towards sites of 
inflammation, injury and cancer. This tropism of MSCs for tumors is thought to result from the 
fundamental role that MSCs play in the context of tissue repair. However, some recruitment 
to non-tumor tissues may also occur.  
Tumors have been described as sites of tissue damage or “wounds that never heal”, as well 
as sites of potential inflammatory cytokine and chemokine production. These properties are 
thought to underlie the general tumor tropism for MSCs (Dvorak 1986). In a pancreatic 
insulinoma mouse model, Direkze et al. demonstrated that 25% of fibroblasts in the tumor 
stroma were of bone marrow origin (Direkze et al. 2004). A series of animal studies have 
demonstrated selective homing of MSCs to gliomas (Dai et al. 2007), pulmonary metastases 
of lung cancer (Mohr et al. 2008), breast cancer metastases (Dwyer and Kerin 2010), ovarian 
cancer (Komarova et al. 2006) and melanoma (Studeny et al. 2004). It is thought that MSCs 
play important roles in the later stages of stromal development as regulators of desmoplastic 
reactions (Hall et al. 2007). To date, the exact mechanisms involved in MSC homing into 
tumors is not completely understood, but it is assumed that the biology is similar to that seen 
in leukocyte recruitment. MSC adhesion to the vascular endothelium is an early step in 
homing of circulating MSCs to tumor tissue. High levels of TNF-α have been reported in 
tumor tissue, which is essential for the upregulation of vascular cell adhesion molecule-1 
(VCAM-1) and other key molecules needed for efficient recruitment to endothelial cells. 
Similar effects can be triggered by IL-1β and IFN-γ (Teo et al. 2012; Uchibori et al. 2013).  
In this context, the following cytokine/receptor pairs and ECM proteins are thought to play a 
role: SDF-1/CXC chemokine receptor-4 (CXCR4), monocyte chemotactic protein-
1/chemokine (C-C motif) receptor 2; hepatocyte growth factor/c-met and vascular endothelial 
growth facor (VEGF)/VEGF receptor (Dwyer et al. 2007; Forte et al. 2006; Menon et al. 2007; 
Schichor et al. 2006; Son et al. 2006).  
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Figure 2 Interactions of MSCs with the tumor microenvironment. Tumors produce various chemokines 
similar to the process of wound healing or inflammation and thereby stimulate MSC recruitment from 
the bone marrow as well as from the blood stream in to the tumor stroma. ECM – extra cellular matrix; 
CAF – cancer associated fibroblasts (Based on the thesis of Zischek 2009) 
 
 
Based on the inherent ability of MSCs to migrate to tumors while avoiding immune clearance, 
they represent promising gene delivery vehicles. The main challenge is to ensure that MSCs 
retain their fundamental properties of migration, differentiation and hypoimmunogenicity after 
genetic modification. To date, in the cancer gene therapy field, MSCs have been used as 
gene delivery vehicles for suicide-, apoptosis-, anti-angiogenesis-, immune-stimulatory genes 
and oncolytic viral vectors (Chen et al. 2008; Dwyer et al. 2011; Loebinger et al. 2009a; 
Niess et al. 2011; Ren et al. 2008; Zischek et al. 2009).  
Conrad et al. used MSCs stably transfected with a reporter or therapeutic transgene under 
the control of the angiogenesis-specific Tie2 promoter which resulted in selective transgene 
expression in angiogenic “hot spots” in tumors. MSCs stably transfected with the therapeutic 
gene herpes simplex virus thymidine kinase (HSV-TK) under the control of the Tie2 
promoter/enhancer were recruited to the vasculature of spontaneous breast cancer tumors or 
orthotopic pancreatic tumors and developed endothelial-like characteristics. Treatment with 
the prodrug ganciclovir (GCV) resulted in a significant reduction of primary tumor growth and 
an improved survival in both tumor models (Conrad et al. 2011; Zischek et al. 2009).  
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In another tumor stroma-specific approach, MSC stably expressing HSV-TK under the 
control of the tumor stroma-specific CCL5 promoter showed significant reduction of the  
primary tumor growth and dramatically reduced the incidence of metastases in an orthotopic 
pancreatic tumor model (Conrad et al. 2011; Zischek et al. 2009). A direct comparison of the 
Tie2 and CCL5 targeting strategies in an orthotopic model of hepatocellular carcinoma 
showed a suppression in tumor growth in both cases, but the CCL5 approach was more 
effective (Niess et al. 2011). 
In another experimental approach, Kim et al. used human umbilical cord-blood derived MSCs 
(UCB-MSC) as gene transfer vehicles for glioma therapy. UCB-MSCs were engineered to 
deliver a secretable trimeric form of tumor necrosis factor-related apoptosis-inducing ligand 
(stTRAIL) via adenoviral transduction mediated by cell-permeable peptides. Intratumoral 
injection of engineered UCB-MSC with TRAIL resulted in a significantly inhibited tumor 
growth and improved survival of glioma-bearing mice (Kim et al. 2008). In a more recent 
study, MSC were transduced with a lentiviral vector encoding stTRAIL and used for 
treatment in a HCC xenograft mouse model. After subcutaneous injection, MSC-TRAIL 
localized to the tumors, inhibited tumor growth and thereby significantly improved survival 
(Deng et al. 2014). 
The goal of this thesis was evaluation of MSCs as gene delivery vehicles for a tumor-
targeted expression of a theranostic gene. Based on its dual function as reporter and therapy 
gene, the sodium iodide symporter (NIS) was used initially for noninvasive imaging of MSC 
recruitment and whole body biodistribution as well as localization, level and duration of NIS 
expression after systemic application of NIS-transduced MSCs. In parallel, the accumulation 
and therapeutic efficacy of 131I was examined in the context of systemic MSC-mediated NIS 
gene transfer. 
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1.4 The sodium iodide symporter (NIS) 
1.4.1 Characterization of the sodium iodide symporter (NIS) 
 
The sodium iodide symporter (NIS) is 
responsible for active uptake of iodide into the 
thyroid gland. It belongs to the sodium/solute 
symporter family (SSF) or solute carrier family 5 
(SCLA5A). NIS is an intrinsic plasma membrane 
glycoprotein with 13 transmembrane domains 
and mediates the active transport of iodide via 
the basolateral membrane into thyroid follicular 
cells. The symporter cotransports one I- anion 
against its electrochemical gradient together 
with two Na+ ions along their electrochemical 
gradient. The functionality of NIS is dependent on the electrochemical sodium gradient that is 
maintained by the oubain-sensitive Na+/K+ ATPase pump. NIS expression is mainly regulated 
by thyroid stimulating hormone (TSH), which initiates a G-protein-mediated signalling 
cascade at the TSH receptor resulting in an increase of NIS mRNA and protein in thyroid 
follicular cells. TSH also regulates the post-transcriptional phosphorylation and plasma 
membrane targeting of NIS (Riedel et al. 2001). The process of iodide organification 
describes the oxidation of iodide by the thyroid peroxidase (TPO) in the presence of H2O2 
and the covalent binding to the tyrosyl residues of thyroglobulin (Tg). The iodinated tyrosyl 
residues couple the thyroid hormones tri-iodithyronine (T3) and tetra-iodothyronine (T4) and 
store them in the colloid space until Tg is taken up in thyroid follicular cells and hormones are 
released into the blood stream. Once there, they play important roles in metabolism, growth 
and maturation of various organ systems, especially at the nervous system (Hingorani et al. 
2010; Spitzweg and Morris 2002). 
Apart from the thyroid gland, NIS is also normally expressed in the stomach, salivary glands 
and lactating mammary glands. The endogenous NIS expression in extra-thyroidal tissues is 
not regulated by TSH and is present at a lower level than in the thyroid gland (Spitzweg and 
Morris 2002). NIS-mediated iodide transport can be inhibited by the Na+/K+-ATPase inhibitor 
ouabain, as well as perchlorate (ClO4-) and thiocyanate (SCN-) (Spitzweg and Morris 2002). 
 
Figure 3 Schematic illustration of the sodium 
iodide symporter (NIS). With permission 
reproduced from Spitzweg et al. (2002) 
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Figure 4 Schematic illustration of a thyroid follicular cell showing the key aspects of thyroid iodine 
transport and thyroid hormone synthesis. With permission by (Spitzweg and Morris 2002). 
 
1.4.2 The sodium iodide symporter as theranostic gene 
 
NIS represents one of the oldest and most successful targets for molecular imaging and 
targeted radionuclide therapy. In differentiated thyroid carcinomas functional NIS expression 
allows postoperative localization and ablation of the thyroid remnant as well as metastases. 
This has been successfully used for more than 70 years in the management of thyroid 
cancer patients. Due to organification of therapeutic radioiodine in follicular thyroid cancer 
cells the tumoral iodide retention time is substantially prolonged leading to sufficiently high 
tumor absorbed doses of 131I thereby providing clinicians with the most effective form of 
systemic anticancer radiotherapy available today. In the routine management of patients with 
differentiated thyroid cancer, radioiodine whole body imaging is able to visualize local and 
metastatic residual or recurrent disease and quantification of tracer uptake allows for exact 
dosimetric calculations of tumor absorbed doses for 131I before therapeutic 131I application, 
thereby aiming at maximal therapeutic efficacy at minimal toxicity in a personalized manner. 
NIS-based thyroid cancer radioiodine therapy is a clinically already approved anticancer 
therapy with a well-understood therapeutic window and safety profile (Hingorani et al. 2010; 
Spitzweg et al. 2001b; Spitzweg and Morris 2002).   
Cloning and characterization of the NIS gene has provided us with a powerful new reporter 
and therapy gene that allowed the development of a promising cytoreductive gene therapy 
strategy based on targeted NIS gene transfer in extrathyroidal tumors followed by the 
diagnostic or therapeutic application of radionuclides. It gives us the possibility to investigate 
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its expression and regulation in thyroidal and non-thyroidal tissues. In its dual role as 
diagnostic and therapeutic gene, NIS has many advantages for the use in cancer gene 
therapy strategies: 
 
1. Normal human gene and protein: NIS expression in cancer cells is unlikely to be toxic 
or to elicit a significant immune response that could limit its efficacy. 
2. Its dual function: NIS as reporter gene allows non-invasive imaging of functional NIS 
expression by 123I-scintigraphy, 123I-SPECT or 124I-PET-imaging, as well as exact 
dosimetric calculations before proceeding therapeutic application of 131I. 
3. High degree of specificity: Extrathyroidal NIS expression is very low not causing 
significant morbidity after 131I application, as known from the extensive experience 
with radioiodine therapy in thyroid cancer. 
4. High degree of efficacy: The NIS-based radioiodine therapy in thyroid cancer is 
already in clinical use with a well-understood therapeutic window and safety profile. 
5. High bystander effect: The NIS gene therapy concept is associated with a substantial 
bystander effect based on the crossfire effect of the beta-emitter 131I with a path 
length of up to 2.4 mm. A bystander effect is desirable for any kind of gene therapy, 
because it reduces the level of transduction efficiency required for a therapeutic 
response.  
 
One of the main advantages of the NIS gene is its applicability as a reporter gene that may 
be employed for real-time non-invasive assessment of biodistribution, gene expression and 
replication of various vector systems. Moreover, it mediates the transport of readily available 
radionuclides, such as 123I, 124I, 125I, 131I, 99mTc, 188Re, 211At or 18F-TFB. Several investigators 
have studied the potential of NIS as reporter gene in various applications, demonstrating that 
in vivo imaging of radioiodine accumulation correlates well with the results of ex vivo gamma 
counter measurements as well as NIS mRNA and protein analyses (Dwyer et al. 2005a; 
Dwyer and Kerin 2010; Richard-Fiardo et al. 2012; Spitzweg et al. 2000; Willhauck et al. 
2007b; Willhauck et al. 2008a; Willhauck et al. 2008c). 123I-scintigraphy, 123I-SPECT (single-
photon emission computed tomography) and 124I-PET (positron emission tomography) 
imaging were usually used in preclinical imaging experiments. Nuclear imaging modalities, 
such as SPECT or PET, reveal the 3-dimensional distribution of radiopharmaceuticals and 
combine excellent sensitivity and high resolution with excellent tissue penetration as 
compared to 2-dimensional gamma camera imaging (Grunwald et al. 2013c; Klutz et al. 
2011a; Richard-Fiardo et al. 2012). For exact anatomical identification of tracer uptake 
regions, especially in orthotopic and metastatic tumor models with small tumors, images can 
be correlated with CT (computer tomography) or MRT (magnetic resonance tomography).  
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In pioneering studies by J.C. Morris and C. Spitzweg, the NIS gene therapy concept was first 
evaluated in a subcutaneous prostate cancer model in mice. Using a replication-incompetent 
adenovirus, where NIS is driven by the prostate-specific antigen (PSA) promoter to achieve 
prostate-specific iodide accumulation, they achieved a significant therapeutic effect after 
radioiodine application (Spitzweg et al. 2000; Spitzweg et al. 1999). To this end, the NIS 
gene therapy concept was evaluated in other non-thyroidal tumor models. For this purpose, 
tissue-specific promoters were investigated such as alpha-fetoprotein (AFP) promoter, 
carinoembryonic antigen (CEA) promoter and the calcitonin promoter for specific NIS 
expression in liver, colon and medullary thyroid cancer cells, respectively (Cengic et al. 2005; 
Scholz et al. 2005; Willhauck et al. 2008c). After the proof of principle of the NIS gene 
therapy concept, the next step was further preclinical evaluation in several animal models 
like rats and beagle dogs before a first phase I clinical study was initiated on radioiodine 
therapy of locally recurrent prostate cancer after local NIS gene transfer (Barton et al. 2008; 
Dwyer et al. 2005b).  
The next critical step towards clinical application of the NIS gene therapy concept has to be 
the evaluation of gene transfer methods that allow sufficient tumor-selective transgene 
expression levels not only after local but also after systemic application to reach metastases.  
Therefore, various non-viral gene delivery systems have been evaluated until now. Delivering 
genes to target organs with synthetic vectors is a vital alternative to virus-based methods. 
For systemic delivery polycationic molecules are used to condense DNA into sub-micrometer 
particles termed polyplexes, which are efficiently internalized into cells, while DNA is 
protected from nucleases. Several polycations, like polyethylenimine (PEI), bear an intrinsic 
endosomic mechanism, which allows the transition of the polyplex from the endosome to the 
cytoplasm (Meyer and Wagner 2006). Non-viral vectors can easily synthesized and convince 
especially by their absent immunogenicity and enhanced biocompatibility. Using 
biodegradable branched polycations complexed with a NIS-expressing plasmid, Klutz et al. 
demonstrated iodide accumulation in subcutaneous HCC xenograft tumors in nude mice 
after intravenous injection. The iodide uptake activity was further high enough for a 
significant therapeutic effect of 131I resulting in an improved survival (Klutz et al. 2009). In a 
more recent study, tumor-selective iodide uptake and therapeutic efficacy of radioiodine was 
observed in a HCC xenograft mouse model after systemic injection of novel polyplexes 
based on linear polyethylenimine (LPEI), shielded by polyethylenglycol (PEG) and coupled 
with an epidermal growth factor receptor-specific ligand GE11 (LPEI-PEG-GE11) which were 
complexed with a NIS expressing plasmid resulting in active ligand-mediated tumor targeting 
(Klutz et al. 2011a). 
Adenovirus Type 5 (Ad5) is one of the most powerful gene vectors in gene therapy 
approaches. Its cellular internalization depends on the presences of the Coxsackie- and 
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Adenovirus Receptor (CAR), which is known to be down-regulated especially in aggressive, 
metastatic cancers. Genetically engineered replication-selective adenoviruses represent very 
efficient gene transfer vehicles with the advantage of potentiating therapeutic efficacy of 
gene therapy by its own oncolytic activity (Duffy et al. 2012). Due to limited virus spread in 
the tumor, virotherapy is ideally combined with therapeutic genes that are associated with a 
bystander effect. In a study of Grünwald et al., a replication-competent adenovirus was used 
in which the E1a gene is driven by the mouse alpha-fetoprotein promoter and the human NIS 
gene is inserted in the E3 region (Ad5-E1/AFP-E3/NIS). Three days after intratumoral virus 
injection, HCC xenografts accumulated approximately 25% ID/g 123I as shown by 
scintigraphy. A single intratumoral injection of Ad5-E1/AFP-E3/NIS (virotherapy) resulted in a 
significant reduction of tumor growth and prolonged survival, as compared to injection of 
saline. Combination of oncolytic virotherapy with radioiodine treatment (radiovirotherapy) led 
to an additional reduction of tumor growth that resulted in markedly improved survival as 
compared to virotherapy alone (Grunwald et al. 2013a). In a next step to reduce the 
adenoviral liver pooling and thereby increase tumor-selective targeting of the adenovirus 
after systemic application, the negatively charged Ad was coated with cationic PAMAM 
(Poly(amidoamine)) dendrimers by non-covalent charge interaction. To further improve 
shielding and targeting we physically coated replication-selective adenoviruses carrying the 
NIS gene with a conjugate consisting of cationic poly(amidoamine) (PAMAM) dendrimer 
linked to the peptidic, epidermal growth factor receptor (EGFR)-specific ligand GE11. 
Systemic injection of the uncoated adenovirus in a liver cancer xenograft mouse model led to 
high levels of NIS expression in the liver due to hepatic sequestration, which were 
significantly reduced after coating as demonstrated by 123I-scintigraphy. Evasion from liver 
pooling resulted in decreased hepatotoxicity and increased transduction efficiency in 
peripheral xenograft tumors. A significantly enhanced oncolytic effect was observed following 
systemic application of dendrimer-coated adenovirus that was further increased by additional 
treatment with a therapeutic dose of 131I (Grunwald et al. 2013b). 
 
Introduction 
14 
 
1.5 Aims of the thesis 
 
Mesenchymal stem cells are currently under investigation as potential clinical therapeutic 
carriers due to their tumor-selective homing capacity, high lineage plasticity and minimal 
ethical concerns associated with their isolation and use. In this thesis MSCs were used for 
tumor targeted NIS gene delivery, where NIS expression was driven by two different 
promoters. The diagnostic and therapeutic potential of the NIS gene has been widely 
described in various tumor models by the use of viral and non-viral gene delivery techniques. 
As a logical consequence after the proof-of-principle studies, the next step towards clinical 
development is the evaluation of systemic gene delivery systems. Here, MSCs are evaluated 
as promising gene delivery vehicles after systemic application for a tumor targeted NIS 
expression.  
In the first step we established and characterized human MSCs that were stably transfected 
with NIS under the control of the unspecific cytomegalovirus (CMV) promoter. The iodide 
uptake activity of the NIS expressing MSCs was first analysed in vitro and confirmed by 
western blot analysis. In addition, a clonogenic assay was performed to determine whether 
131I sequestered by NIS-expressing MSCs would be able to kill adjacent hepatocellular 
cancer (HCC) cells in cocultures through the crossfire effect of 131I. In vivo, the efficacy and 
therapeutic potential of MSC-mediated NIS gene transfer was studied in a subcutaneous 
HCC xenograft mouse model after systemic injection. 
Following proof-of-principle of MSC-mediated NIS gene delivery, in the next step, we aimed 
at enhancing tumor stroma-specificity of MSC-mediated NIS gene delivery by application of a 
tumor stroma specific promoter. For this purpose, MSCs were stably transfected with a NIS 
expressing plasmid, in which NIS was driven by the tumor stroma specific CCL5/RANTES 
promoter (RANTES-NIS-MSC). Tumor-specificity and therapeutic efficacy of 131I were 
evaluated after systemic application of RANTES-NIS-MSC in the subcutaneous HCC 
xenograft mouse model as well as in an orthotopic HCC xenograft model in nude mice using 
radioiodine imaging (123I-scintigraphy and 124I-PET) as well as MR imaging for tumor growth 
control in the orthotopic tumor model.  
In the final step, tumor-specificity and therapeutic efficacy of MSC-mediated NIS gene 
delivery was evaluated in a metastasis model. To this end, a hepatic colon cancer 
metastases model was established based on intrasplenic tumor cell injection. After systemic 
injection of NIS-expressing MSCs under the control of the CCL5 promoter, the NIS-mediated 
iodide uptake activity and the therapeutic potential of radioiodine were analysed using 
gamma camera and PET imaging as well as MR imaging for tumor growth control at the 
therapy studies. 
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2.1 Abstract 
 
Due to its dual role as reporter and therapy gene, the sodium iodide symporter (NIS) allows 
non-invasive imaging of functional NIS expression by 123I-scintigraphy or 124I-PET imaging 
before the application of a therapeutic dose of 131I. NIS expression provides a novel 
mechanism for the evaluation of mesenchymal stem cells (MSCs) as gene delivery vehicles 
for tumor therapy. 
In the current study we stably transfected bone marrow-derived CD34- MSCs with NIS cDNA 
(NIS-MSC), which revealed high levels of functional NIS protein expression. In mixed 
populations of NIS-MSCs and hepatocellular cancer (HCC) cells clonogenic assays showed 
a 55% reduction of HCC cell survival after 131I application. We then investigated body 
distribution of NIS-MSCs by 123I-scintigraphy and 124I-PET imaging following i.v. injection of 
NIS-MSCs in a HCC xenograft mouse model demonstrating active MSC recruitment into the 
tumor stroma which was confirmed by immunohistochemistry and ex vivo gamma counter 
analysis. Three cycles of systemic MSC-mediated NIS gene delivery followed by 131I 
application resulted in a significant delay in tumor growth.  
Our results demonstrate tumor-specific accumulation and therapeutic efficacy of radioiodine 
after MSC-mediated NIS gene delivery in HCC tumors, opening the prospect of NIS-
mediated radionuclide therapy of metastatic cancer using MSCs as gene delivery vehicles. 
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2.2 Introduction 
 
Mesenchymal stem cells (MSC) are pluripotent progenitor cells with high proliferative and 
self renewal capacity, which play a key role in maintenance and regeneration of diverse 
tissues based on their ability to differentiate into cells of connective tissue lineages, including 
bone, fat, cartilage and muscle (Fritz and Jorgensen 2008; Pittenger et al. 1999; Studeny et 
al. 2004). In the course of tissue injury, or during chronic inflammation, MSCs can contribute 
to tissue remodeling by their mobilization and subsequent recruitment to the site of injury. 
While the exact mechanisms by which circulating progenitor cells home to remodeling 
tissues remain unclear, it is thought that chemokine biology and integrins underlie tissue-
specific homing of stem cells (Conrad et al. 2007; Von Luttichau et al. 2005).  
Tumors are composed of malignant tumor cells and the “benign” tumor stromal compartment 
that includes blood vessels, infiltrating inflammatory cells, extracellular matrix and stromal 
fibroblasts. This tumor stroma plays a key role in tumor growth, tumor angiogenesis and 
metastatic potential of a tumor, and has therefore become an important target for tumor 
therapy (Fritz and Jorgensen 2008; Studeny et al. 2004). The process of tumor stroma 
formation is similar to that seen in wound healing which results in tissue remodeling with 
recruitment and high proliferation of mesenchymal cells. We and others have shown that 
MSCs are actively recruited to growing tumor stroma where they differentiate into diverse 
tumor stroma-associated cell types including cells that comprise the tumor vasculature and 
stromal fibroblast-like cells (Conrad et al. 2007; Nakamizo et al. 2005; Pittenger et al. 1999; 
Spaeth et al. 2009; Studeny et al. 2004; Zischek et al. 2009). Based on their intrinsic tumor 
homing capacity, MSCs have gained attention as potential vehicles for delivering therapeutic 
genes to tumor environments after systemic application, potentially providing a means to 
deliver therapeutic genes not only to the primary tumor, but also to tumor metastases. A 
series of recent reports have provided the proof of principle of MSC-mediated gene delivery 
demonstrating successful tumor-selective engraftment of ex vivo transduced MSCs 
(Loebinger et al. 2009a; Nakamizo et al. 2005; Studeny et al. 2002; Studeny et al. 2004; Xin 
et al. 2007; Zischek et al. 2009). 
NIS, an intrinsic transmembrane glycoprotein with 13 putative transmembrane domains, is 
responsible for the ability of thyroidal cells to concentrate iodide, the first and rate-limiting 
step in the process of thyroid hormonogenesis, which can be effectively blocked by the 
competitive inhibitor perchlorate (NaClO4) (Hingorani et al. ; Spitzweg and Morris 2002). Due 
to its expression in follicular cell-derived thyroid cancer cells, NIS provides the molecular 
basis for the diagnostic and therapeutic application of radioiodine, which has been 
successfully used for more than 70 years for the treatment of thyroid cancer patients, and 
represents the most effective form of systemic anticancer radiotherapy available today 
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(Spitzweg and Morris 2002). Since its cloning in 1996, the NIS gene has been identified and 
characterized as a therapeutic gene for the treatment of thyroidal or extrathyroidal tumors 
following selective NIS gene transfer into tumor cells. This allows the therapeutic application 
of radioiodine and alternative radionuclides, such as 188Re and 211At (Hingorani et al. ; 
Spitzweg and Morris 2002; Willhauck et al. 2007b; Willhauck et al. 2008a). NIS also 
represents one of the most promising reporter genes available, which allows direct 
noninvasive imaging of functional NIS expression by 123I-scintigraphy and 124I-PET imaging, 
as well as exact dosimetric calculations before proceeding to therapeutic application of 131I 
(Dingli et al. 2003b; Groot-Wassink et al. 2004; Spitzweg and Morris 2002). NIS has many 
characteristics of an optimal reporter and therapy gene, as it is a non-immunogenic protein 
with a well-defined body biodistribution and expression, that mediates the transport of readily 
available radionuclides, such as 131I, 123I, 125I, 124I, 99mTc, 188Re or 211At (Hingorani et al. ; 
Spitzweg and Morris 2002).  
The field of gene therapy has made considerable strides in the last decade through the 
development of new vector systems, including engineered MSCs, and an increasing 
repertoire of therapeutic genes. The application of NIS in its role as reporter gene allows 
detailed characterization and direct monitoring of in vivo vector biodistribution as well as 
localization, level, and duration of transgene expression after viral or non-viral gene delivery. 
These are recognized as critical elements in the design of clinical gene therapy trials (Baril et 
al. ; Dingli et al. 2003b; Spitzweg and Morris 2002). Several research groups, including our 
own, have demonstrated the potential of NIS as reporter gene in various applications, 
demonstrating that in vivo imaging of radioiodine accumulation by 123I- or 99mTc-scintigraphy 
as well as 123I-SPECT/CT fusion imaging correlates well with the results of ex vivo gamma 
counter measurements as well as NIS mRNA and protein analysis (Blechacz et al. 2006; 
Carlson et al. 2009; Goel et al. 2007; Klutz et al. 2009; Merron et al. 2007; Spitzweg et al. 
2007; Trujillo et al. ; Willhauck et al. 2007a). In addition, PET imaging using 124I provides 
significant advantages for exact localization and quantitative analysis of NIS-mediated 
radioiodine accumulation due to enhanced resolution and sensitivity (Dingli et al. 2006; 
Groot-Wassink et al. 2004). 
In the current study, we applied MSCs as gene delivery vehicles for tumor-targeted NIS gene 
expression in a hepatoma mouse model. Based on its dual function as reporter and therapy 
gene, NIS was used initially for noninvasive imaging of MSC recruitment and whole body 
biodistribution as well as localization, level and duration of NIS expression after systemic 
application of NIS-transduced MSCs. The therapeutic capacity of 131I therapy was 
subsequently evaluated after systemic administration of NIS expressing MSCs. 
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2.3 Methods 
 
Cell culture 
The MSCs used express CD73 and CD105, but lack the myelogenic markers CD34, CD14, 
CD45, and MHC class II and are thus difficult to define (Conrad et al. 2002; Thalmeier and 
Huss 2001). A clonal cell line derived from SV40 large T antigen immortalized MSCs from 
human bone marrow was used for the outlined studies (Thalmeier and Huss 2001). The cells 
grow adherently and continuously in cell culture and retain significant pluripotency (Conrad et 
al. 2002; Thalmeier and Huss 2001). MSCs were cultured in RPMI (Invitrogen, Life 
Technologies Inc., Paisley, UK) supplemented with 10% fetal bovine serum (v/v; PAA, 
Pasching, Austria) and 1% penicillin/streptomycin.  
For animal experiments the human hepatocellular carcinoma cell line Huh7 (JCRB 0403) 
was cultured in DMEM/F12 (Invitrogen, Darmstadt, Germany) supplemented with 10% fetal 
bovine serum (v/v; PAA), 5% L-Glutamine (GibcoBRL, Karlsruhe, Germany) and 1% 
penicillin/streptomycin. 
For in vitro studies, the hepatocellular carcinoma HepG2 cell line (ATCC-HB-8065) was 
cultured in RPMI (Invitrogen) supplemented with 10% fetal bovine serum (v/v; PAA) and 1% 
penicillin/streptomycin.  
All cell lines were maintained at 37°C and 5% CO2 in an incubator with 95% humidity. 
 
Stable transfection of mesenchymal stem cells 
Wild-type MSCs (WT-MSCs) were stably transfected with the expression vector CMV-NIS-
pcDNA3 (full length NIS cDNA coupled to the cytomegalovirus (CMV) promoter, kindly 
provided by Dr. S.M. Jhiang, Ohio, State University, Columbus, OH) using LipofectAMINE 
Plus reagent (Invitrogen) under serum-free conditions according to the manufacturer’s 
recommendations. After transfections, cells were incubated for 24 h in regular growth 
medium. Selection was performed with 0.5 mg/ml geneticin (Invitrogen) in RPMI medium 
containing 10% fetal bovine serum and 1% penicillin/streptomycin. Surviving clones were 
isolated and subjected to screening for iodide uptake activity (see below). The stably 
transfected cell line with the highest levels of iodide accumulation among approximately 60 
colonies screened was termed NIS-MSC and used for the experiments. 
 
125I uptake assay 
Following transfection, iodide uptake of NIS-MSCs was determined at steady-state 
conditions as described previously (Spitzweg et al. 1999). Results were normalized to cell 
survival measured by cell viability assay (see below) and expressed as cpm/A 490 nm. 
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Cell viability assay 
Cell viability was measured using the commercially available MTS assay (Promega Corp., 
Mannheim, Germany) according to the manufacturer’s recommendations as described 
previously (Spitzweg et al. 1999). 
 
In vitro clonogenic assay 
HepG2 cells cocultured with NIS-MSCs or WT-MSCs were incubated for 7 h with 29.6 MBq 
(0.8 mCi) 131I in Hank’s balanced salt solution (HBSS, GibcoBRL) supplemented with 10 µM 
NaI and 10 mM HEPES (pH 7.3) at 37°C. After incubation with 131I, the MSCs were 
separately removed by incubation with 1% trypsin in PBS for 1 min, which did not affect 
attachment of HepG2 cells. Thereafter, HepG2 cells were detached by incubation with 0.05% 
trypsin/0.02% EDTA in PBS for 10 min at 37°C. The HCC cells were then plated at cell 
densities of 50, 100, 250, 500, 750, 1000 und 2000 cells/well in 12-well plates. Two weeks 
later, after colony development, cells were fixed with methanol, stained with crystal violet, 
and HCC colonies containing more than 50 cells were counted. Parallel experiments were 
performed using HBSS without 131I and all values were adjusted for plating efficiency. The 
percentage of survival represents the percentage of cell colonies after 131I treatment, 
compared with mock treatment with HBSS. Purity of HepG2 cells after selective 
trypsinization was confirmed by phase-contrast microscopy and by immunofluorescence 
analysis using cell type-specific antibodies (vimentin and keratin) in parallel experiments. 
 
Membrane preparation and Western Blot analysis 
Membrane protein was prepared from NIS-MSC and WT-MSC cells followed by Western blot 
analysis as described previously (Spitzweg et al. 1999). A mouse monoclonal NIS-specific 
antibody (kindly provided by J.C. Morris, Division of Endocrinology, Mayo Clinic and Medical 
School, Rochester, MN) was applied at a dilution of 1:1000. As loading controls, the blots 
were reprobed with a monoclonal antibody directed against β-actin (Sigma).  
 
Establishment of Huh7 xenograft tumors 
Huh7 xenograft tumors were established in female CD1 nu/nu mice (Charles River, Sulzfeld, 
Germany) by s.c. injection of 5 x 106 Huh7 cells suspended in 100 µl PBS into the flank 
region. The animals were maintained under specific pathogen-free conditions with access to 
mouse chow and water ad libitum. The experimental protocol was approved by the regional 
governmental commission for animals (Regierung von Oberbayern).  
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MSC application and radioiodine biodistribution studies in vivo 
Experiments were initiated when the implanted tumors reached a diameter of 3 to 5 mm, 
after a 10-day pretreatment with intraperitoneal (i.p.) injections of 2 µg L-T4/d (Henning, 
Sanofi-Aventis, Germany), diluted in 100 µl PBS, to suppress thyroidal iodide uptake. WT-
MSCs or NIS-MSCs were applied via the tail vein at a concentration of 5 x 105 cells/500µl. 
Two groups of mice were established and treated as follows: (a) three i.v. applications of NIS-
MSC in four day intervals (n=24); (b) three i.v. applications of WT-MSC in four day intervals 
(n=9). As an additional control, in a subset of mice injected with NIS-MSC (n=9) the specific 
NIS-inhibitor sodium-perchlorate (NaClO4, 2 mg per mouse) was injected i.p. 30 min prior to 
123I administration. 72 h after the last MSC application, 18.5 MBq (0.5 mCi) 123I was injected 
i.p. and iodide biodistribution was assessed using a gamma camera equipped with UXHR 
collimator (Ecam, Siemens, Germany) as described previously (Willhauck et al. 2007b; 
Willhauck et al. 2008a). Regions of interest were quantified and expressed as a fraction of 
the total amount of applied radionuclide per gram tumor tissue (after postmortem weighing). 
The retention time within the tumor was determined by serial scanning after radionuclide 
injection. Dosimetric calculations were done according to the concept of medical internal 
radiation dose, with the dosis factor of RADAR-group (www.dosisinfo-radar.com). 
In an additional group of mice injected with NIS-MSCs (n=5), radioiodine biodistribution was 
also monitored using 124I-PET imaging after i.v. injection of 20 MBq 124I. PET imaging was 
performed as described previously (Groot-Wassink et al. 2004; Rominger et al.). In brief, PET 
data were acquired in list-mode format over 40 min on a Siemens Inveon P120 microPET 
(Siemens Medical Solutions, Munich, Germany). Dynamic emission recordings acquired in 
list mode were reconstructed using a combined reconstructing algorithm with two OSEM3D 
iterations as described by Rominger et al. (Rominger et al.). 
 
Analysis of radioiodine biodistribution ex vivo 
For ex vivo biodistribution studies, mice were injected with NIS-MSCs (n=8) or WT-MSCs 
(n=3) as described above followed by i.p. injection of 18.5 MBq (0.5 mCi) 123I. A subset of 
NIS-MSC injected mice (n=3) were treated with NaClO4 prior to 123I administration as an 
additional control. Five hours after 123I injection, mice were sacrificed and organs of interest 
were dissected, weighed and 123I accumulation was measured in a gamma counter. Results 
were reported as percentage of injected dose per organ (% ID/organ). 
 
Analysis of NIS mRNA expression using quantitative real-time PCR 
Total RNA was isolated from Huh7 tumors or other tissues using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s recommendations and 
quantitative real-time PCR (qPCR) was performed as described previously (Klutz et al. 
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2009).  
 
Immunohistochemical analysis of NIS protein and SV40 large T antigen expression 
Immunohistochemical staining of paraffin-embedded tissue sections derived from Huh7 
tumors after i.v. MSC application was performed as described previously (Spitzweg et al. 
2007). As primary antibodies, the mouse monoclonal NIS-specific antibody (see above) or 
the mouse monoclonal anti-SV40 large T Ag antibody (Calbiochem/Merck, Darmstadt, 
Germany) were used at a dilution of 1:1000 and 1:2000, respectively. 
 
Radioiodine therapy study in vivo 
Following a 10-day L-T4 pretreatment as described above, two groups of mice were 
established receiving 55.5 MBq 131I 48 h after the last of three NIS-MSC (n=15) or WT-MSC 
(n=15) applications in two-day-intervals (each 5 x 105 cells/500 µl PBS), respectively. This 
cycle was repeated once 24 h after the last 131I application. 24 h after these two treatment 
cycles one additional MSC (5 x 105 cells) injection was administered followed by a third 131I 
(55.5 MBq) injection 48 later. As control, one further group of mice were treated with saline 
instead of 131I after injection of NIS-MSC (n=15). A further control group was injected with 
saline only (n=15). Tumor sizes were measured before treatment and daily thereafter for up 
to seven weeks. Tumor volume was estimated using the equation: tumor volume = length x 
width x height x 0.52. Mice were sacrificed when tumors started to necrotize, exceed a tumor 
volume of 1500 mm3, in case of weight loss of more than 10%, or impairment of breathing as 
well as drinking and eating behavior. 
Experiments were repeated twice and tumor volumes are expressed as mean of 15 mice per 
group. 
 
Indirect immunofluorescence assay 
Indirect immunofluorescence analysis using a Ki67-specific antibody and an antibody against 
CD31 was performed on frozen sections as described previously (Willhauck et al. 2007b). 
Immunostainings that had to be compared quantitatively were captured at identical 
illumination conditions, with identical exposure time and system settings for digital image 
processing.  
Quantification of cellular proliferation (percentage of Ki67 positive cells in the tumor) and 
blood vessel density (percentage of CD31 positive area in the tumor) was performed by 
evaluation of 10 high power fields per tumor (6 animals per group) using ImageJ software 
(NIH, USA).  
Results are presented as means ± standard deviation, statistical significance was calculated 
using students t-test. 
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Statistical methods 
All in vitro experiments were carried out in triplicates. Results are represented as mean ± SD 
of triplicates. Statistical significance of in vitro experiments was tested using Student´s t test. 
Statistical significance of in vivo experiments has been calculated using Man-Whitney U test.  
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2.4 Results 
 
In vitro characterization of MSCs stably expressing NIS 
After stable transfection of immortalized human bone marrow derived CD34- MSCs with a 
NIS expressing plasmid (CMV-NIS-pcDNA3) (NIS-MSC), the transfected cells showed a 12-
fold increase in NIS-mediated iodide uptake activity, which could be blocked upon treatment 
with the NIS-specific competitive inhibitor perchlorate (Fig. 1a). In contrast, in WT-MSCs no 
perchlorate-sensitive iodide uptake above background level was observed.   
NIS protein expression in NIS-transfected MSCs was confirmed by Western blot analysis 
using a mouse monoclonal NIS-specific antibody (Fig. 1b). The antibody recognizes the 
carboxy-terminus of human NIS and revealed a major band of a molecular mass of 
approximately 80-90 kDa in NIS-MSCs, which was not detected in WT-MSCs.  
A time course of iodide uptake in NIS-MSCs and WT-MSCs showed that in NIS-MSCs, 
iodide accumulation reached half-maximal levels within 10-15 min and became saturated at 
40-50 min (Fig. 1c). No NIS-specific iodide accumulation above background level was 
observed in WT-MSCs. 
A clonogenic assay was then performed to determine whether 131I sequestered by NIS-MSCs 
would be able to kill adjacent HCC cells in cocultures through the crossfire effect of 131I (Fig. 
1d). NIS-MSCs or WT-MSCs cocultured with HCC cells were incubated in HBSS containing 
29.6 MBq 131I for 7 h. HCC cells, cocultured with WT-MSCs (ratio 1:1) showed no significant 
cell killing after incubation with 131I. In contrast, in cocultures of HCC cells and NIS-MSCs 
(ratio 1:1), HCC cells, which have no iodide uptake activity per se, a 55% reduction in cell 
survival was seen (Fig. 1d). 
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Figure 1 In vitro analysis of MSCs stably expressing NIS. 125I uptake was measured in NIS-MSCs 
compared to WT-MSCs (Fig. 1a). NIS-MSCs showed a 12-fold increase in perchlorate-sensitive 125I 
accumulation. In contrast, no perchlorate-sensitive iodide uptake above background level was 
observed in WT-MSCs (Fig. 1a) (p<0.001). Analysis of NIS protein expression in NIS-MSCs as 
compared to WT-MSCs by Western Blot analysis (Fig. 1b). NIS protein was detected as a major band 
of a molecular mass of 80-90 kDa which was not detected in WT-MSCs (Fig. 1b). MW, molecular 
weight. Time course of iodide uptake in NIS-MSCs and WT-MSCs (Fig. 1c). Iodide accumulation 
reached half-maximal levels in NIS-MSCs within 10-15 min and became saturated at 40-50 min, while 
WT-MSCs showed no iodide accumulation (Fig. 1c). In an in vitro clonogenic assay mixed populations 
of WT-MSCs and HCC cells as well as NIS-MSCs and HCC cells (ratio 1:1) were exposed to 29.6 
MBq 131I (Fig. 1d). In HCC cells cocultured with NIS-MSCs a 55% reduction of cell survival was 
measured, whereas HCC cells cocultured with WT-MSCs survived the 131I incubation to almost 100% 
(Fig. 1d) (p<0.001). Results represent means of three plated cell densities ± SD (100, 500 and 1000 
cells per well). 
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In vivo radioiodine biodistribution studies 
In nude mice harboring HCC xenografts 5 x 105 NIS- or WT-MSCs were injected i.v. via the 
tail vein three times in four day intervals. 72 h following the last MSC injection, 18.5 MBq 123I 
was administered and radioiodine distribution was monitored using a gamma camera. While 
no significant iodide accumulation was detected in tumors after application of WT-MSC (Fig. 
2c), significant iodide accumulation was observed in 74 % of Huh7 tumors following NIS-
MSC application, in addition to physiologic iodide accumulation in thyroid gland, stomach and 
bladder (Fig. 2a). As determined by serial scanning, a maximum of approximately 7% to 9% 
ID/g 123I was accumulated after application of NIS-MSCs with a biological half-life of 4 h. 
Considering a tumor mass of 1g and an effective half-life of 3 h for 131I, a tumor absorbed 
dose of 43.7 ± 7.7 mGy/MBq 131I was calculated (Fig. 2d). To confirm that tumoral iodide 
uptake was mediated by functional NIS expression, a subset of NIS-MSC injected mice 
received NaClO4 30 minutes prior to 123I administration. In all experiments, a single injection 
of 2 mg NaClO4 completely blocked tumoral iodide accumulation in addition to abolishing 
iodide uptake in stomach and thyroid gland (Fig. 2b).  
In a subset of mice, radioiodine biodistribution was also monitored using 124I-PET imaging 
after i.v. injection of 20 MBq 124I (Figs. 2e,f). Three-dimensional data were generated using 
iterative reconstructions of list-mode data (0-40 min), which gave better anatomical definition. 
Significant tumor-selective iodide accumulation was observed following NIS-MSC application 
thereby confirming the findings of the planar gamma camera imaging, but allowing a more 
detailed three-dimensional analysis of tumoral iodide accumulation. One hour after iodide 
application a maximum tumoral iodide uptake of approximately 5-7% ID/g was measured. 
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Figure 2 123I gamma camera imaging of mice harboring Huh7 tumors after MSC-mediated NIS gene 
delivery three hours following 123I administration (Fig. 2a-c). After three i.v. applications of NIS-MSCs 
significant tumor-specific iodide accumulation was induced (7-9 % ID/g 123I) (Fig. 2a), which was 
completely abolished upon pretreatment with NaClO4 (Fig. 2b). In contrast, mice injected with WT-
MSCs showed no tumoral iodide uptake (Fig. 2c). Iodide was also accumulated physiologically in 
thyroid, stomach and bladder (Fig. 2a, c). Time course of 123I accumulation in Huh7 tumors after three 
i.v. NIS-MSC applications followed by injection of 18.5 MBq 123I as determined by serial scanning (Fig. 
2d). Maximum tumoral radioiodine uptake was 7-9% ID/g tumor with an average effective half-life of 3 
h for 131I. 124I PET imaging of mice harboring Huh7 tumors after MSC-mediated NIS gene delivery (Fig. 
2e, f). After three i.v. applications of NIS-MSCs significant tumor-specific iodide accumulation was 
confirmed by PET imaging (left: sagittal slice orientation, right: coronal slice orientation). 
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Ex vivo radioiodine biodistribution studies 
Ex vivo biodistribution studies confirmed significant iodide uptake in tumors following three 
systemic i.v. applications of NIS-MSCs resulting in a tumoral iodide uptake of 2.5% to 3% 
ID/organ 123I 5 hours after radioiodine injection. In contrast, mice injected with WT-MSCs 
showed no significant tumoral iodide uptake. No significant iodide uptake levels were 
observed in the non-target organs lung, liver, spleen or kidney (Fig. 3). In both groups, the 
thyroid gland and the stomach accumulated approximately 40% and 39% 123I ID/organ 
resulting from endogenous expression of NIS in thyroid and stomach. It is important to point 
out that due to the exquisite regulation of thyroidal NIS expression by thyroid-stimulating 
hormone (TSH), 123I accumulation in the thyroid gland can effectively be downregulated by 
thyroid hormone treatment as shown in humans (Wapnir et al. 2004). In addition, iodide 
accumulation in the stomach is mostly a result from pooling of gastric juices, which is more 
prominent in mouse experiments than usually seen in humans due to the anesthesia for a 
prolonged period during imaging procedure (Klutz et al. 2009; Spitzweg and Morris 2002) 
(data not shown). Administration of perchlorate in mice injected with NIS-MSCs significantly 
blocked iodide uptake in tumors and in physiologically NIS-expression tissues including 
thyroid gland and stomach (Fig. 3).  
 
 
Figure 3 Evaluation of iodide biodistribution ex vivo five hours following injection of 18.5 MBq 123I. 
Tumors in NIS-MSC-injected mice showed high perchlorate-sensitive iodide uptake activity (approx. 
2.5-3% ID/organ), while no significant iodide accumulation was measured in tumors after injection of 
WT-MSCs or in nontarget organs. Results are reported as percent of injected dose per organ ± SD. 
 
 
Analysis of NIS mRNA expression by qPCR 
In order to assess the relative NIS mRNA expression after systemic MSC application, mRNA 
from tumors and control tissues was extracted and analyzed by qPCR with NIS-specific 
oligonucleotide primers. While low levels of NIS mRNA expression were detected in tumors 
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after WT-MSC administration, significant levels of NIS mRNA were detected in tumors of 
mice following systemic NIS-MSC injection (Fig. 4). As expected, administration of the 
competitive NIS inhibitor perchlorate had no influence on NIS mRNA expression in tumors 
treated with NIS-MSCs. In other organs, including liver, lung, kidneys and spleen no 
significant NIS mRNA expression was observed after systemic NIS-MSC injection.  
 
 
 
Figure 4 Analysis of NIS mRNA expression in Huh7 tumors and non-target organs by qPCR. While 
only a low background level of NIS mRNA expression was detected in untreated tumors (which was 
set as one arbitrary unit) or tumors injected with WT-MSC, significant levels of NIS mRNA expression 
were induced in Huh7 tumors after three applications of NIS-MSCs with or without NaClO4 
pretreatment (p<0.05). In addition, no significant NIS mRNA expression was detected in non-target 
organs after three applications of NIS-MSCs. Results are reported as NIS/GAPDH ratios. 
 
 
Immunohistochemical analysis of NIS protein expression in Huh7 tumors 
To better determine MSC distribution, tumor specimens were immunohistochemically stained 
with NIS- and SV40 large T Ag-specific antibodies. SV40 large T Ag was used to immortalize 
the MSC and could thus be used for ex vivo detection of the adoptively transferred MSC. 
NIS-specific immunoreactivity was detected throughout the tumor stroma with most 
prominent staining in areas neighboring blood vessels in tumors of mice that were injected 
with NIS-MSCs (Fig. 5a, arrows). Distribution of NIS-specific immunoreactivity was similar to 
the localization of SV40 large T Ag (Fig 5b). Lungs, liver, and kidneys showed no detectable 
NIS or SV40 large T Ag immunoreactivity (data not shown). In contrast, strong accumulation 
of SV40 large T Ag-expressing cells was observed in the spleens of mice after administration 
of NIS-MSCs (Fig. 5f), while no NIS-specific immunoreactivity was detected (Fig. 5e). WT-
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MSC-injected mice showed no significant NIS protein expression in tumors (Fig. 5c) and 
other organs like lungs, liver, kidneys or spleen (Fig. 5g). However, after WT-MSC application 
SV40 large T Ag-specific immunoreactivity was widely detectable in implanted Huh7 tumors 
(Fig. 5d) as well as in spleen (Fig. 5h) demonstrating efficient MSC recruitment into the tumor 
stroma after systemic application. The presence of MSC in the spleen may result either from 
the direct recruitment of the cells [6], or from active filtration of the exogenously applied MSC 
from the peripheral circulation. 
 
Figure 5 Immunohistochemical 
staining of Huh7 tumors after 
application of NIS-MSCs (Figs. 
5a, b) or WT-MSCs (Figs. 5c, 
d). After application of NIS-
MSCs Huh7 tumors revealed 
NIS-specific immunoreactivity 
throughout the tumor stroma, 
which was most prominent in 
the vicinity of blood vessels 
(Fig. 5a), with a similar 
distribution of SV40 large T Ag-
positive cells (Fig. 5b). After 
application of WT-MSCs no 
NIS-specific immunoreactivity 
was detected in Huh7 tumors 
(Fig. 5c), while strong 
cytoplasmic SV40 large T Ag-
staining was detected, in 
particular in the vicinity of blood 
vessels (Fig. 5d). Other organs 
like lung, liver, and kidneys 
showed no detectable NIS 
protein expression and no 
SV40 large T Ag staining (data 
not shown). In contrast, strong 
accumulation of SV40 large T 
Ag-expressing cells was 
detected in the spleen of mice 
that were injected with NIS-
MSCs (Fig. 5f) or WT-MSC 
(Fig. 5h), while no NIS-specific 
immunoreactivity was detected 
(Figs. 5e, g). 
 
 
 
 
 
Radioiodine therapy studies in vivo after MSC-mediated systemic NIS gene transfer 
The effect of therapeutic 131I was then evaluated in concert with application of NIS-MSC. The 
131I therapy regime was optimized using small groups of mice (n = 4) and showed the best 
results when mice were treated with three cycles of NIS engineered MSCs followed by 131I 
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application (data not shown). Mice treated with NIS-MSCs followed by application of saline or 
mice treated with WT-MSCs followed by application of 131I , or saline treated mice all showed 
an exponential tumor growth. In contrast, NIS-transduced (NIS-MSCs) and 131I-treated 
tumors showed a significant delay in tumor growth (p=0.001703 (NaCl) and p=0.008103 
(WT-MSC)) (Fig. 6a). Mice showed no major adverse effects of radionuclide or MSC 
treatment in terms of lethargy or respiratory failure. 
Upon completion of the therapy study, mice were sacrificed and tumors were dissected and 
processed for immunfluorescence analysis. Immunfluorescence analysis using a Ki67-
specific antibody (green) and an antibody against CD31 (red, labelling blood vessels) 
showed striking differences between mice treated with NIS-MSC/131I (Fig. 6b) and mice 
treated with WT-MSC/131I (Fig. 6c) as well as mice treated with NIS-MSC/NaCl (Fig. 6d). 
Control tumors showed a Ki67-index of approx. 45 ± 8.7% and a mean vessel density of 5 ± 
0.45%, whereas tumors treated with NIS-MSC and 131I exhibited a lower intratumoral blood 
vessel density of 1.85 ± 0.25% and a proliferation index of 25 ± 4.1% after 131I therapy. 
 
 
Figure 6 Two groups of mice were established receiving 55.5 MBq 131I 48 h after the last of three NIS-
MSC (n=15) or WT-MSC (n=15) applications in two-day-intervals, respectively. This cycle was 
repeated once 24 h after the last 131I application. 24 h after these two treatment cycles, one additional 
MSC injection was administered followed by a third 131I (55.5 MBq) injection 48 later. 131I therapy after 
NIS-MSC application resulted in a significant delay in tumor growth as compared with the control 
groups, that were injected with WT-MSC followed by 131I (p=0.008103; n=15), with NIS-MSC followed 
by saline (p=0.001703; n=15) or with saline only (n=15) (Fig. 6a). Immunofluorescence analysis using 
a Ki67-specific antibody (green) and an antibody against CD31 (red, labeling blood vessels) showed 
decreased proliferation (Ki67, 25 ± 4.1 %) and reduced blood vessel density (CD31, 1.85 ± 0.25%) in 
tumors of mice treated with NIS-MSC followed by 131I treatment (Fig. 6b) as compared to tumors of 
mice injected with WT-MSC and 131I (Fig. 6c) or mice treated with NIS-MSC and saline (Fig. 6d) (Ki67, 
45 ± 8.7%; CD31, 5 ± 0.45%). Slides were counterstained with Hoechst Nuclear stain. Magnification 
200x.  
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2.5 Discussion 
 
NIS represents one of the oldest and most successful targets for molecular imaging. Cloning 
of the NIS gene has provided a versatile new reporter and therapy gene which has paved the 
way for the development of a novel cancer gene therapy strategy based on NIS-mediated 
radionuclide imaging and therapy (Hingorani et al. ; Spitzweg and Morris 2002). In previous 
studies in a prostate cancer model, we made use of a prostate-specific promoter to drive 
tissue-specific NIS expression after ex vivo NIS transduction of prostate cancer cells or local 
adenoviral in vivo NIS gene transfer. This approach demonstrated a significant therapeutic 
effect after application of 131I or alternative radionuclides, such as 188Re and 211At (Kakinuma 
et al. 2003; Spitzweg et al. 2001a; Spitzweg et al. 2000; Spitzweg et al. 1999; Willhauck et al. 
2007b; Willhauck et al. 2008a). Our work in the prostate cancer model and subsequent work 
in other tumor models, including medullary thyroid, colon and hepatocellular cancer (Dwyer 
et al. 2005a; Dwyer et al. 2005b; Herve et al. 2008; Klutz et al. 2009; Li et al. ; Peerlinck et al. 
2009; Scholz et al. 2005; Spitzweg et al. 2007; Willhauck et al. 2007b; Willhauck et al. 
2008c), have demonstrated the potential of NIS as a combined reporter and therapy gene.  
One of the major hurdles for safe clinical application of the NIS gene-based therapy concept 
is optimal tumor targeting, with low toxicity, and high transduction efficiency for gene delivery 
vectors, with the ultimate aim of systemic vector application for the treatment of metastatic 
disease.  
Relatively few studies have investigated NIS-targeted radionuclide therapy of metastatic 
cancer after systemic NIS gene delivery. The application of an oncolytic measles virus or an 
oncolytic vesicular stomatitis virus in a multiple myeloma mouse model was found to allow 
the monitoring of virus replication by radioiodine gamma camera or SPECT imaging as well 
as stimulation of oncolytic potency of the virus by combination with 131I therapy (Dingli et al. 
2004; Goel et al. 2007). In a recent study, we used NIS as reporter and therapy gene to 
demonstrate the high potential of synthetic polymeric vectors based on pseudodendritic 
oligoamines with high intrinsic tumor affinity for tumor-specific delivery of the NIS gene. After 
intravenous application of NIS polyplexes in a syngeneic neuroblastoma mouse model, NIS-
mediated radioiodine accumulation was mainly restricted to the tumor, and sufficiently high 
for a significant delay of tumor growth (Klutz et al. 2009). 
In the current study we utilized MSCs as gene delivery vehicles for tumor-targeted NIS gene 
delivery in a human hepatocellular cancer xenograft mouse model. Previous studies have 
shown that MSCs can efficiently migrate and engraft into the tumor stroma of tumor lesions 
representing the basis for the paradigm of the “Trojan horse” approach in which MSCs are 
used as shuttle vectors for delivery of therapeutic genes into critical parts of growing tumors 
(Conrad et al. 2011; Studeny et al. 2004). In a mouse model it was shown that MSCs 
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expressing TRAIL can provide targeted delivery of this pro-apoptotic agent to breast cancer 
metastases to the lung (Loebinger et al. 2009a). Similarly, MSCs transduced to express IFNβ 
or the immunostimulatory chemokine CX3CL1 have been shown to provide an antitumor 
effect in various murine cancer models, including glioma (Nakamizo et al. 2005), breast 
(Studeny et al. 2004), melanoma (Studeny et al. 2002) and colorectal cancer (Xin et al. 
2007). In two previous studies we have demonstrated active homing of herpes simplex virus 
type 1 thymidine kinase (HSV-Tk)-transduced MSCs into primary pancreatic or breast cancer 
tumor stroma that resulted in significant reduction of tumor growth and in one case reduced 
incidence of metastases after application of ganciclovir (Conrad et al. 2011; Zischek et al. 
2009). 
Here MSCs stably transfected with NIS under control of the CMV promoter (NIS-MSC) 
revealed high levels of functional NIS protein expression that resulted in a 55% reduction of 
survival of HCC cells when cocultured with NIS-MSCs in an 131I in vitro clonogenic assay. 
This demonstrated a significant bystander effect based on the crossfire effect of the β-emitter 
131I with a path length of up to 2.4 mm. Following systemic application of NIS-MSCs via the 
tail vein, 74% of implanted HCC tumors showed tumor-specific 123I accumulation as imaged 
by gamma camera scintigraphy with accumulation of approx. 7% to 9% ID/g, and a biological 
half-life of 4 hours. In contrast, control mice showed no tumoral radioiodine uptake, 
confirming that the observed iodide accumulation in the tumors was mediated by functional 
NIS expression. In vivo 123I-scintigraphic imaging confirmed by ex vivo biodistribution 
experiments revealed significant tumoral radioiodine accumulation. No iodide uptake was 
measured in nontarget organs, including liver, lungs, spleen or kidneys. Tumoral NIS 
expression was further verified by real time qPCR as well as NIS-specific immunoreactivity, 
which showed expression throughout the tumor stroma with most prominent staining in areas 
neighboring blood vessels. Interestingly, SV40 large T Ag immunostaining revealed strong 
accumulation of MSCs in the spleen without detection of NIS-specific immunoreactivity or 
iodide accumulation. These data suggest that MSCs were recruited to the spleen but did not 
undergo the same program of differentiation and activation, and therefore did not express the 
therapeutic gene.  
Most of the studies investigating the potential of MSCs as gene delivery vehicles have 
addressed the issue of biodistribution and tumor-specific recruitment of MSCs mainly by ex 
vivo analysis of reporter gene expression. Our data demonstrate the potential of NIS as a 
dynamic reporter gene offering the possibility of noninvasive in vivo tracking of NIS-MSC 
homing and engraftment at the tumor site by 123I-scintigraphy. This allows a detailed analysis 
of in vivo biodistribution of genetically modified MSCs as well as exact characterization of 
localization and level of transgene expression, an essential prerequisite for exact planning 
and monitoring of clinical gene therapy trials.  
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Our data are consistent with a recently published study by Rad et al. (Rad et al. 2009), who 
used superparamagnetic iron oxide-labeled NIS-transduced AC133+ progenitor cells to carry 
the NIS gene to sites of breast cancer xenografts in a nude mouse model. After i.v. 
application progenitor cells were successfully tracked by magnetic resonance imaging (MRI), 
while 99mTc-SPECT imaging demonstrated NIS gene expression at the tumor site confirming 
tumor-specific recruitment of stem cells (Rad et al. 2009). A similar approach was 
investigated by Loebinger et al., who labeled human MSCs with iron oxide nanoparticles, 
which allowed tracking of MSCs to lung metastases in vivo using MRI (Loebinger et al. 
2009b). In addition, bioluminescent imaging was used to monitor luciferase-transduced MSC 
homing and engraftment in a syngeneic breast cancer mouse model (Klopp et al. 2007). 
In addition to 123I gamma camera imaging, we used small animal whole body positron 
emission tomography (PET) using 124I as radiotracer. Despite the widespread availability of 
123I-scinitgraphy, PET imaging is attractive for tracking the delivery and tumoral engraftment 
of NIS-MSCs due to its higher sensitivity and enhanced resolution (Dingli et al. 2006; Groot-
Wassink et al. 2004). In addition, fusion of PET with computed tomography (CT) images 
allows a more robust biodistribution analysis and clearly aids in correlative diagnosis in 
clinical oncology. With translation from animal to human studies in mind, PET/CT could be 
the optimal method to study MSC biodistribution, followed by quantification of radioiodine 
accumulation and exact dosimetric calculations. We have demonstrated the feasibility of 
monitoring MSC biodistribution by 124I-PET allowing a more detailed three-dimensional 
analysis of NIS-mediated radioiodine accumulation. In support of our data, MSC engraftment 
and proliferation in tumor stroma of microscopic tumors has successfully be monitored by 
18F-FHBG-PET imaging using herpes simplex virus type 1 thymidine kinase as reporter gene 
(Hung et al. 2005).  
The ability to monitor MSC distribution effectively sets the stage for therapeutic application of 
131I. As detailed above, and shown in the current therapy study, the application of NIS-
transduced MSCs allows noninvasive imaging of their recruitment and engraftment at the 
tumor site, and also provides a powerful anticancer strategy taking advantage of NIS as a 
potent therapy gene. NIS expression allows a significant bystander effect based on the 
crossfire effect of the β-emitters 131I (path length of up to 2.4 mm) or 188Re (path length of 10 
mm) that are both transported by the protein. NIS-mediated uptake of 131I or 188Re in NIS-
transduced MSCs therefore can kill neighboring tumor cells, but also can target a significant 
radiation dose to the tumor stroma, which has been recognized as a crucial and vulnerable 
target for tumor therapy. Due to its function as a reporter gene, and its association with a 
significant bystander effect, NIS represents an ideal therapy gene in the context of stem cell 
based gene therapy which was demonstrated in the current study. After three cycles of 
repetitive MSC injections followed by 131I administration, experimental HCC-xenografts 
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showed a significant reduction in tumor growth. In addition, immunofluorescence analysis of 
tumor tissue showed markedly reduced proliferation and decreased blood vessel density in 
the NIS-MSC/131I treated mice. To date, only relatively few studies have demonstrated the 
feasibility of MSCs as gene delivery vehicles for the treatment of malignant tumors. Zischek 
et al. demonstrated significant reduction of pancreatic tumor growth and incidence of 
metastases using HSV-Tk transfected MSCs after treatment with glanciclovir (Zischek et al. 
2009). In a related study, intratumorally injected TRAIL-secreting umbilical cord blood-
derived MSCs significantly reduced tumor growth in a glioma tumor model (Kim et al. 2010). 
However, these studies lack the unique dual function of the NIS gene as detailed here.  
MSCs are known to have immunosuppressive functions that may influence therapeutic 
efficacy. We believe that due the transient nature of the application of the engineered MSCs 
in concert with the removal of all adoptively applied MSC in the context of therapy in the 
current study, and based on our previous studies outlined above, this phenomenon is of 
minor relevance. A negative effect on therapy was not seen in experiments using syngeneic 
MSC expressing a suicide gene in syngeneic immunocompetent mice (Conrad et al. 2011; 
Zischek et al. 2009). 
In conclusion, our data demonstrate the high potential of genetically engineered MSCs as 
tumor-selective delivery vehicles for the human NIS gene after systemic application. NIS as a 
potent and well characterized reporter gene allowed detailed noninvasive characterization of 
in vivo biodistribution of MSCs by analysis of functional NIS expression by 123I-scintigraphy 
and 124I-PET imaging, which is an essential prerequisite for exact planning and monitoring of 
the application of NIS as therapy gene. Moreover, in parallel studies, 131I administration leads 
to delayed tumor growth. This study therefore opens the exciting prospect of NIS-mediated 
radionuclide therapy of metastatic cancer taking advantage of the tumor-selective homing of 
MSCs and the bystander effect of the NIS gene therapy concept.  
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3.1 Abstract 
 
The tumor-homing property of mesenchymal stem cells (MSC) has led to their use as 
delivery vehicles for therapeutic genes. The application of the sodium iodide symporter (NIS) 
as therapy gene allows non-invasive imaging of functional transgene expression by 123I-
scintigraphy or PET-imaging, as well as therapeutic application of 131I or 188Re. Based on the 
critical role of the chemokine RANTES/CCL5 secreted by MSCs in the course of tumor 
stroma recruitment, use of the RANTES/CCL5 promoter should allow tumor stroma-targeted 
expression of NIS after MSC-mediated delivery. 
Using a human hepatocellular cancer (HCC) xenograft mouse model (Huh7) we investigated 
distribution and tumor recruitment of RANTES-NIS-engineered MSCs after systemic injection 
by gamma camera imaging. 123I-scintigraphy revealed active MSC recruitment and CCL5 
promoter activation in the tumor stroma of Huh7 xenografts (6.5% ID/g 123I, biological half-
life: 3.7 h, tumor-absorbed dose: 44.3 mGy/MBq). In comparison, 7% ID/g 188Re was 
accumulated in tumors with a biological half-life of 4.1 h (tumor-absorbed dose: 128.7 
mGy/MBq). Administration of a therapeutic dose of 131I or 188Re (55.5 MBq) in RANTES-NIS-
MSC treated mice resulted in a significant delay in tumor growth and improved survival 
without significant differences between 131I and 188Re. 
These data demonstrate successful stromal targeting of NIS in HCC tumors by selective 
recruitment of NIS-expressing MSCs and by use of the RANTES/CCL5 promoter. The 
resulting tumor-selective radionuclide accumulation was high enough for a therapeutic effect 
of 131I and 188Re opening the exciting prospect of NIS-mediated radionuclide therapy of 
metastatic cancer using genetically engineered MSCs as gene delivery vehicles. 
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3.2 Introduction 
 
Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading 
cause of cancer-related death worldwide (Parkin et al. 2005). The only available, potentially 
curative treatment options, such as liver transplantation, surgical resection, or radiofrequency 
ablation are reserved for patients with early-stage HCC. However, more than half of the 
patients with HCCs are diagnosed at an intermediate or advanced tumor stage with only 
limited, palliative treatment options, leading to a poor prognosis for these patients (Parkin et 
al. 2005; Pinter et al. 2012). Growing HCC require an active tumor stroma with extensive 
vasculature with high endothelial cell turnover, numerous cancer-associated fibroblasts, 
inflammatory cells and increased levels of cytokines and chemokines such as TNF-α, TGF-β, 
IL-6, IL-10, CCL2/MCP-1, CCL3 and RANTES/CCL5 for effective tumor growth 
(Braunersreuther et al. 2012; Niess et al. 2011). The tumor stroma is therefore recognized as 
an important therapeutic target in the treatment of HCCs.  
Mesenchymal stem cells (MSC) play a key role in the maintenance and regeneration of 
diverse tissues. In the course of tissue injury, or during chronic inflammation, MSCs 
contribute to tissue remodeling by their recruitment to sites of tissue injury (Aquino et al. 
2010). We and others have shown that MSCs are strongly recruited into the stroma of many 
malignant tumors. It is thought that growing tumor is seen by the body as a “chronic wound” 
and MSC act as progenitor cells for components of the tumor stroma (Aquino et al. 2010; 
Conrad et al. 2007; Conrad et al. 2011; Dwyer et al. 2010; Knoop et al. 2011; Niess et al. 
2011; Zischek et al. 2009). The tropism of MSCs for tumors represents the basis for the 
paradigm of the “Trojan horse” approach. Due to their intrinsic tumor homing capacity, MSCs 
are under development as cellular vehicles for the targeted delivery of therapeutic genes into 
the stroma of malignant tumors (Klopp et al. 2007; Knoop et al. 2011; Niess et al. 2011; 
Zischek et al. 2009). 
Central issues that must be addressed with this therapeutic approach include the 
development of restricted transgene expression to spare potential damage to non-tumor 
tissues, enhanced non-invasive in vivo imaging techniques that could be applied to patients, 
and the development of more potent therapy gene strategies.  
Karnoub et al. recently demonstrated recruitment of MSCs into the tumor stroma of breast 
cancer, followed by their induced expression of the CC-chemokine RANTES/CCL5 
(Regulated on Activation, normal T-cell Expressed and presumably Secreted)/CCL5 
(Karnoub et al. 2007). CCL5 is a chemoattractant of monocytes, eosinophils and activated 
CD4 T cells, which signals through the G protein-coupled receptors (GPCR) CCR1, CCR3 
and CCR5 (Zlotnik and Yoshie 2000). CCL5 expression is associated with increased tumor 
neovascularization, as well as enhanced cancer growth and metastasis by autocrine and 
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paracrine activation of tumor cells and through the recruitment of stromal cell types to sites of 
primary tumor growth (Karnoub et al. 2007). 
Due to its expression in follicular cell-derived thyroid cancer cells, the sodium iodide 
symporter (NIS) provides the molecular basis for diagnostic and therapeutic application of 
radioiodine for the treatment of thyroid cancer patients. Cloning of NIS has therefore allowed 
the development of a new therapeutic strategy for the treatment of tumors without 
endogenous NIS expression based on targeted, tumor-selective NIS gene transfer followed 
by administration of 131I or other radionuclides that are transported by NIS, such as 188Re or 
211At (Hingorani et al. ; Spitzweg and Morris 2002; Willhauck et al. 2007b; Willhauck et al. 
2008a). 188Re is characterized by a shorter physical half-life and decay properties that are 
seen as superior to 131I, and thus may provide a powerful tool to enhance the therapeutic 
efficacy of NIS-mediated radionuclide therapy, in particular because of its enhanced crossfire 
effect (max path length of up to 10.4 mm) (Klutz et al. 2011b; Willhauck et al. 2007b). 
Importantly, the use of NIS as a theranostic gene offers the possibility of direct non-invasive 
molecular scintigraphy and PET imaging allowing dosimetric calculations as a crucial 
prerequisite for the exact planning of therapy studies (Dingli et al. 2003b; Groot-Wassink et 
al. 2004; Klutz et al. 2011b; Spitzweg and Morris 2002; Willhauck et al. 2007b). 
In our previous studies, human MSCs were stably transfected with a sodium iodide 
symporter (NIS)-expressing plasmid, where NIS was driven by the broadly expressed CMV 
promoter. Using NIS as reporter gene, active MSC recruitment into the tumor stroma of HCC 
xenografts was demonstrated after systemic injection. In addition, repetitive MSC injections 
followed by 131I administration showed a significant reduction in tumor growth with an 
improved survival (Knoop et al. 2011). Since MSCs are known to be recruited also in non-
tumor tissues such as spleen or skin, the use of the unspecific CMV promoter might be 
disadvantageous due to transgene expression in these non-target organs with the risk of 
extratumoral toxicity. Therefore, in the current study, we have made use of the 
RANTES/CCL5 promoter to biologically target NIS transgene expression in engineered 
human MSCs to the stroma of HCC xenografts. In parallel, the accumulation and therapeutic 
efficacy of 131I was examined in direct comparison to 188Re in the context of systemic MSC-
mediated NIS gene transfer. 
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3.3 Methods 
 
Cell culture 
Establishment and characterization of MSCs and cultivation of the human HCC cell line Huh7 
(JCRB 0403) have been described previously (Knoop et al. 2011).  
 
Plasmid construct  
The full length NIS cDNA was removed from the pcDNA3 expression vector (kindly provided 
by Dr S.M. Jhiang, Ohio State University, Columbus, OH, USA) by restriction digestion using 
XbaI and HindIII, agarose gel purified and ligated into the expression vector pcDNA3-
CCL5Pro. CCL5Pro-NIS was removed and ligated in the pCMV/Bsd vector (Invitrogen/Life 
technologies) using the restriction enzyme HindIII resulting in pCMV/Bsd-RaPro-hNIS. The 
sequence of the CCL5 promoter used -972 of the upstream region and the complete 
5´untranslated region (Nelson et al. 1993). The vector included a CMV controlled Bsr2 
Blasticidin resistance gene to select transfected cells at a blasticidin concentration of 5µg/ml. 
 
Mesenchymal stem cells 
Wild-type MSCs stably transfected with pCMV/Bsd-RaPro-hNIS were established as 
described previously (Knoop et al. 2011). The clone expressing the highest levels of NIS 
mRNA was subsequently referred to as RANTES-NIS-MSC and used for all further 
experiments. To prepare cells for injection into mice, cells were detached from culture flasks, 
washed three times with 1x PBS and resuspended in 1x PBS at a concentration of 500.000 
cells per 500µl. 
 
Establishment of Huh7 xenograft tumors 
Huh7 xenograft tumors were established in female CD1 nu/nu mice (Charles River, Sulzfeld, 
Germany) as described previously (Knoop et al. 2011). The experimental protocol was 
approved by the regional governmental commission for animals (Regierung von 
Oberbayern).  
 
MSC application and radionuclide biodistribution analysis in vivo 
Experiments were started when a tumor size of 3 to 5 mm was reached and following a 10-
day pretreatment with L-T4 as described previously (Knoop et al. 2011). The pretreatment 
schedule was based on a study by Di Cosmo et al. using a dose generally accepted as a 
supraphysiological LT-4 dose (10 µg L-T4/100 g body weight) (Di Cosmo et al. 2009). The 
mice used in our experiments weighed between 20 – 25 g and therefore a dose of 2 µg L-
T4/mice per day was chosen. WT-MSCs or RANTES-NIS-MSCs were injected into the tail 
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vein at a concentration of 5 x 105 cells/500µl PBS. Two groups of mice were established with 
following treatments: (a) three i.v. applications of RANTES-NIS-MSC in four day intervals 
(n=48); (b) three i.v. applications of WT-MSC in four day intervals (n=9). As an additional 
control, in a subset of mice injected with RANTES-NIS-MSC (n=18) the specific NIS-inhibitor 
sodium-perchlorate (NaClO4, 2 mg per mouse) was injected i.p. 30 min prior to radionuclide 
administration. 72 h after the last MSC application, 18.5 MBq 123I or 111 MBq 188Re (188ReO4- 
perrenhate) were injected i.p. and radionuclide biodistribution was assessed using a gamma 
camera equipped with UXHR collimator (Ecam, Siemens, Germany) as described previously 
(Willhauck et al. 2007b; Willhauck et al. 2008a); Knoop et al., 2011).  
Biodistribution analysis of radionuclides was also performed ex vivo after mice were injected 
with RANTES-NIS-MSCs (n=16) or WT-MSCs (n=6) as described above followed by i.p. 
injection of 18.5 MBq 123I or 111 MBq 188Re, respectively. As an additional control, a subset of 
RANTES-NIS-MSC injected mice (n=8) were pretreated with NaClO4. Gamma counter 
analysis was performed as described previously (Knoop et al. 2011). 
 
NIS mRNA analysis by quantitative real-time PCR 
Analysis of NIS mRNA expression by quantitative real time PCR (qPCR) was performed as 
described previously (Knoop et al. 2011). 
 
Radionuclide therapy studies in vivo 
Following a 10-day L-T4 pretreatment as described above, four groups of mice were 
established receiving 55.5 MBq 131I (sodium iodide; GE Healthcare Buchler GmbH, 
Braunschweig, Germany) or 188Re (188ReO4- perrhenate; ITG GmbH, Garching, Germany) 48 
h after the final of three RANTES-NIS-MSC (RANTES-NIS-MSC + 131I, n=15; RANTES-NIS-
MSC + 188Re, n=15) or WT-MSC (WT-MSC + 131I, n=15; WT-MSC + 188Re, n=15) 
applications in two-day-intervals (each 5 x 105 cells/500 µl PBS), respectively. This cycle was 
repeated once 24 h after the last radionuclide application. 24 h later one additional MSC (5 x 
105 cells) injection was applied, followed by another radionuclide (55.5 MBq 131I or 188Re, 
respectively) injection 48 h later (Fig. 5a). As a control group, mice were injected with 
RANTES-NIS-MSC (n=15) followed by application of saline. Another control group received 
saline only (n=15). The follow up of mice including tumor measurements were performed as 
outlined previously (Knoop et al., 2011). 
 
Indirect immunofluorescence assay 
Immunofluorescence staining of frozen sections was performed as described previously 
(Knoop et al. 2011) using following primary antibodies: hNIS (mouse monoclonal, provided by 
J.C. Morris, Division of Endocrinology, Mayo Clinic and Medical School, Rochester, MN), 
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mouse RANTES/CCL5 (goat polyclonal, AF478, R&D Systems, Minneapolis, USA), SV40 
large T-antigen (mouse monoclonal, Calbiochem/Merck, Darmstadt, Germany), CD31 (rat 
monoclonal, Pharmingen/BD, New York, USA) or Ki67 (rabbit polyclonal, Abcam, Cambrigde, 
UK). Staining and evaluation of proliferation and vessel density were preformed as described 
previously (Knoop et al. 2011). 
 
Statistical methods 
Statistical significance of in vitro experiments was tested using Student´s t test. Statistical 
significance of in vivo experiments has been calculated using Man-Whitney U test. 
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3.4 Results 
 
Radionuclide biodistribution studies after in vivo NIS gene transfer 
Significant iodide accumulation was observed in 67% of Huh7 tumors following application of 
RANTES-NIS-MSCs (Fig. 1a). In contrast, after application of WT-MSCs no tumoral iodide 
accumulation was measured (Fig. 1c). Serial imaging revealed a tumoral uptake of 
approximately 6.5% ID/g 123I after application of RANTES-NIS-MSCs with a biological half-life 
of 3.7 h (Fig. 1g). Considering a tumor mass of 1g, and an effective half-life of 3.5 h for 131I, a 
tumor absorbed dose of 44.3 ± 8.6 mGy/MBq 131I was calculated. In comparison, 
approximately 7% ID/g 188Re was concentrated in 67% of Huh7 tumors, with a biological half 
life of 4.1 h (Fig. 1d, g). With an effective half-life of 3.5 h for 188Re, a tumor absorbed dose of 
128.7 ± 28.2 mGy/MBq 188Re was determined. Physiologic accumulation of radionuclides 
was also observed in thyroid gland and stomach due to endogenous NIS expression as well 
as in the bladder due to renal excretion of radionuclides (Fig. 1a, c, d, f). In a subset of mice 
injected with RANTES-NIS-MSCs, pretreatment with perchlorate (NaClO4; 2mg) 30 min prior 
to injection of the respective radionuclide, completely abolished radionuclide uptake in the 
tumor as well as in thyroid gland and stomach, confirming that the observed radionuclide 
accumulation is indeed NIS-mediated (Fig. 1b, e). As expected, physiologic radionuclide 
accumulation in non-target organs (thyroid gland, stomach, and bladder) was also seen after 
WT-MSC injection (Fig. 1c, f). As outlined above, in 1/3 of the animals no specific 
radionuclide accumulation after RANTES-NIS-MSCs injection was observed, however, by 
immunohistochemistry it was shown, that MSCs were recruited into the tumor stroma to a 
lower extent (Suppl. Fig. 1), resulting in a radionuclide accumulation which was obviously 
below the detection limit.  
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Figure 1 Radionuclide biodistribution studies in vivo. Gamma-camera imaging of mice harboring 
Huh7 tumors after mesenchymal stem cell (MSC)-mediated sodium iodide symporter (NIS) gene 
delivery 3 hours following 123I or 188Re administration. After three intravenous i.v. applications of 
RANTES-NIS-MSCs significant tumor-specific iodide (a) and rhenium (d) accumulation was induced, 
which was completely abolished upon pretreatment with NaClO4 (b) and (e). In contrast, mice injected 
with WT-MSCs showed no tumoral iodide (c) or rhenium (f) uptake. Radionuclides were also 
accumulated physiologically in thyroid, stomach and bladder. (g) Time course of 123I and 188Re 
accumulation in Huh7 tumors after three i.v. RANTES-NIS-MSC applications followed by injection of 
18.5 MBq 123I or 111 MBq 188Re, respectively, as determined by serial scanning. Maximum tumoral 
radioiodine uptake was 6.5% ID/g tumor and 7% ID/g tumor for 188Re, respectively. 
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Supplemental Figure 1 Immunohistochemical staining of radionuclide-negative Huh7 tumors 
after application of RANTES-NIS-MSCs. Radionuclide-negative Huh7 tumors revealed lower levels 
of NIS-specific immunoreactivity throughout the tumor stroma after application of RANTES-NIS-MSCs 
(a) with a similar distribution of SV40 large T Ag-positive cells (b) and in the presence of strong 
RANTES-specific immunoreactivity (c). Magnification: NIS, SV40 large T AG and RANTES/CCL5 
staining: x200 
 
 
Analysis of NIS protein expression by indirect immunofluorescence 
The distribution of MSCs in tumors and non-target organs such as liver, kidney and spleen 
was determined in more detail by immunofluorescence staining using NIS-, SV40 large T Ag- 
and RANTES/CCL5-specific antibodies. H&E stainings of all organs or tumors are provided 
(Fig 2 d, h, l, p, t). Immortalization of MSCs via SV40 large T Ag provides a useful marker for 
the ex vivo detection of adoptively transferred MSCs. NIS-specific immunoreactivity based on 
RANTES/CCL5 promoter activity, was detected throughout the tumor stroma, predominantly 
in the vicinity of blood vessels, which paralleled the localization of SV40 large T Ag and the 
distribution of RANTES/CCL5 expression (Fig 2 a-d). Liver and kidneys showed no 
detectable NIS, SV40 large T Ag or RANTES/CCL5 immunoreactivity (Fig. 2 e-l). In contrast, 
a high density of SV40 large T Ag-expressing cells was detected in the spleen after 
RANTES-NIS-MSC application (Fig. 2n), while no NIS- and RANTES/CCL5-specific 
immunofluorescence staining was observed (Fig. 2 m, o) demonstrating restricted transgene 
expression. Injection of WT-MSCs resulted in SV40 large T Ag- and RANTES/CCL5-specific 
immunofluorescene staining in tumors (Fig. 2 r, s) demonstrating active tumoral recruitment 
of MSCs after i.v. application. In contrast, no NIS-specific immunostaining was observed after 
WT-MSC gene transfer (Fig. 2 q).  
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Figure 2 Immunhistochemical staining of Huh7 tumors and non-target organs after application 
of RANTES-NIS-MSCs or WT-MSCs. After application of RANTES-NIS-MSCs Huh7 tumors revealed 
NIS-specific immunoreactivity throughout the tumor stroma (a) with a similar distribution of SV40 large 
T Ag- (b) and RANTES/CCL5-positive cells (c). Other organs, like liver or kidney showed no 
detectable NIS, SV40 large T Ag or RANTES/CCL5 protein expression (e-g, i-k). In contrast, strong 
accumulation of SV40 large T Ag-expressing cells was detected in the spleen of mice that where 
injected with RANTES-NIS-MSCs (n), while no NIS- (m) or RANTES/CCL5-specific immunoreactivity 
(o) was detected. After application of WT-MSCs no NIS-specific immunoreactivity was detected in 
Huh7 tumors (q), while strong cytoplasmatic SV40 large T Ag (r) and RANTES/CCL5 (s) staining was 
detected. Slides were counterstained with Hoechst Nuclear stain. H&E stainings of Huh7 tumors (d), 
liver (h), kidney (l) and spleen (p) after injection of RANTES-NIS-MSC and tumors of mice injected 
with WT-MSCs (t) are provided. Magnification (NIS and SV40 large T AG staining: x200; 
RANTES/CCL5 staining: x100) (bv – blood vessel). 
 
 
Ex vivo radionuclide biodistribution studies 
Significant levels of tumoral iodide and rhenium uptake were confirmed after application of 
RANTES-NIS-MSCs by ex vivo biodistribution studies revealing a radionuclide uptake of 3 – 
3.5% ID/organ 123I or 188Re four hours after radionuclide injection. In non-target organs (lung, 
liver, spleen, kidney) no specific radionuclide accumulation was detected. The competitive 
NIS inhibitor perchlorate significantly blocked radionuclide uptake in tumors of mice injected 
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with RANTES-NIS-MSCs (Fig. 3). Significant radionuclide accumulation was also detected in 
tissues that physiologically express NIS (stomach, thyroid gland) and in the bladder due to 
renal elimination of radionuclides (Spitzweg et al., 2002; Spitzweg et al., 2001). The thyroid 
gland and the stomach accumulated approximately 40% and 39% ID/organ, respectively, for 
123I and 15% ID/organ and 40% ID/organ, respectively, for 188Re (data not shown). The 
effective half-life in the thyroid gland was approx. 38 h for 131I and only 6.5 h for 188Re. In this 
regard it is important to outline that NIS expression is exclusively regulated by thyroid 
stimulating hormone (TSH) in the thyroid gland, which allows effective downregulation of 
radionuclide accumulation in the thyroid gland by thyroid hormone pretreatment as shown by 
Wapnir et al. (Wapnir et al., 2004). Moreover, during prolonged anaesthesia for imaging 
purposes gastric juices are pooled in the stomach which results in significantly higher gastric 
radionuclide accumulation than routinely observed in humans. In the bladder radionuclide 
accumulation and retention time can be minimized by stimulation of diuresis thereby lowering 
the delivered dose and side effects to bladder and adjacent tissues. 
 
 
Figure 3 Evaluation of radionuclide biodistribution ex vivo 4 hours following injection of 18.5 
MBq 123I or 111 MBq 188Re. Tumors in RANTES-NIS-MSC-injected mice showed high perchlorate-
sensitive radionuclide uptake activity (~ 3 – 3.5% ID/organ), while no significant radionuclide 
accumulation was measured in non-target organs. Results are reported as percent of injected dose 
per organ ± SD. 
 
 
NIS mRNA analysis by qPCR 
mRNA was isolated from tumors and non-target organs (liver, lung, kidney and spleen) after 
systemic MSC injection and analyzed by qPCR using NIS-specific oligonucleotide primers. 
Systemic injection of RANTES-NIS-MSCs in tumor-bearing mice resulted in significantly 
increased levels of NIS mRNA in tumors, whereas no significant NIS mRNA expression was 
detected in non-target organs (Fig. 4).  
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Figure 4 Analysis of NIS mRNA expression in Huh7 tumors and non-target organs by 
quantitative real-time PCR (qPCR). While only a low background level of NIS mRNA expression was 
detected in tumors injected with WT-MSCs, significant levels of NIS mRNA expression were induced 
in Huh7 tumors after three applications of RANTES-NIS-MSCs with or without NaClO4 pretreatment. In 
non-target organs like liver, lung, kidney or spleen no NIS mRNA expression was detected. 
 
 
Radionuclide therapy studies in vivo after MSC-mediated systemic NIS gene transfer 
The effect of therapeutic radionuclides (131I and 188Re) was then compared and contrasted in 
the context of RANTES-NIS-MSC treatment. Control mice treated with RANTES-NIS-MSCs 
followed by saline application, mice treated with WT-MSCs followed by application of 131I or 
188Re, or mice treated with saline only showed an exponential tumor growth and had to be 
killed after 3 – 4 weeks (Fig. 5a). In contrast, RANTES-NIS-MSC and 131I- or 188Re-treated 
tumors showed a dramatic control of growth (day 24: p=0.02 (NaCl) and p=0.05 (WT-MSC)) 
that extended through the end of the experiment (nine weeks) (Fig. 5a) and which resulted in 
an improved survival (Fig. 5b). The application of 188Re did not result in an obvious increase 
in therapeutic efficacy as compared with 131I, but enhanced therapeutic effects would be 
difficult due to the dramatic effects of 131I treatment in this experimental setting. No major 
adverse effects of radionuclide or MSC treatment were observed in terms of lethargy or 
respiratory failure. 
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Figure 5 Radionuclide therapy studies in vivo after MSC-mediated systemic NIS gene transfer. 
Four groups of mice were established receiving 55.5 MBq 131I or 188Re 48 hours after the final of three 
RANTES-NIS-MSC or WT-MSC applications in 2-day-intervals. This cycle was repeated once 24 
hours after the last radionuclide application. Twenty-four hours after these two treatment cycles, one 
additional MSC injection was administered followed by a third 131I or 188Re (55.5 MBq) injection 48 
hours later. 131I and 188Re therapy after RANTES-NIS-MSC application resulted in a significant delay in 
tumor growth as compared with the control groups, that were injected with WT-MSCs followed by 131I 
or 188Re or with RANTES-NIS-MSCs followed by saline or with saline only (p<0.05) (a). The 
significantly reduced tumor growth was associated with markedly improved survival (Kaplan-Meier-
Plot, p<0.05) (b). 
 
 
At the end of the observation period, mice were sacrificed, tumors dissected followed by H&E 
staining (Fig. 6f, g) and immunofluorescence staining using a Ki67-specific antibody (green, 
labelling proliferating cells) and a CD31-specific antibody (red, labelling blood vessels). 
Striking differences were observed between mice treated with WT-MSC (Fig. 6a, b) or mice 
treated with saline (Fig. 6c) as compared to mice treated with RANTES-NIS-MSC followed by 
application of 188Re or 131I (Fig. 6d, e). Tumors of mice injected with RANTES-NIS-MSC 
followed by NaCl showed a Ki67-index of approx. 62 ± 8% and a mean vessel density of 4.25 
± 0.7% (Fig. 6h, i), whereas tumors treated with RANTES-NIS-MSC and 188Re or 131I showed 
significantly reduced levels of intratumoral proliferation index (20.3 ± 5%) and blood vessel 
density (1 ± 0.2%) (Fig. 6h, i). 
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Figure 6 Immunofluorescence analyses of radionuclide therapy studies. Immunofluorescence 
analysis of tumors using a Ki67-specific antibody (green, labeling proliferating cells) and an antibody 
against CD31 (red, labeling blood vessels). As compared to control tumors (a – c), RANTES-NIS-MSC 
and 188Re or 131I treated tumors showed visible differences in tumor cell proliferation and blood vessel 
density (d, e). Quantification of blood vessel density and tumor cell proliferation showed significantly 
reduced tumor cell proliferation (20.3 ± 5%)(f) and blood vessel density (1 ± 0.2%)(g) after systemic 
RANTES-NIS-MSC application in 188Re or 131I treated tumors as compared to control tumors (Ki67: 62 
± 8%, p<0.001; CD31: 4.25 ± 0.7%, p<0.01)(f, g). Slides were counterstained with Hoechst nuclear 
stain. H&E stainings of control and treated tumors (f, g). Magnification x200. 
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3.5 Discussion 
 
Several groups including our own have demonstrated that mesenchymal stem cells (MSCs) 
are actively recruited into growing tumor stroma where they play a major role in forming the 
tumor’s fibrovascular network (Karnoub et al. 2007; Knoop et al. 2011; Niess et al. 2011; 
Zischek et al. 2009). MSC recruitment to tumor stroma is thought to be driven by high local 
concentrations of inflammatory chemokines and growth factors, such as MCP-1/CCL2, IL-
8/CXCL8, RANTES/CCL5, SDF-1α/CXCL12 among others (Karnoub et al. 2007; Spaeth et 
al. 2008). Within the tumor stroma, MSCs can differentiate into carcinoma-associated 
fibroblasts or pericyte-like cells where they contribute to tumor growth through secretion of 
inflammatory and pro-angiogenic growth factors like VEGF, PDGF, SDF-1α/CXCL12, EGF, 
IGF, IL-6 and RANTES/CCL5 (Spaeth et al. 2009). This tropism of MSCs for tumor 
environments makes them uniquely suited as tumor stroma-selective gene delivery vehicles. 
In models of pancreatic, breast and liver cancer we have applied MSCs transduced with 
herpes simplex virus type 1 thymidine kinase (HSV-Tk) and demonstrated active tumor 
stroma-selective recruitment of MSCs that significantly reduced tumor growth and 
metastasizing potential after treatment with ganciclovir (Niess et al. 2011; Zischek et al. 
2009). 
MSCs have been used to deliver a diverse array of agents, including interferon-β, cytosine 
deaminase, tumor-necrosis factor-related apoptosis-inducing ligand, the immunostimulatory 
chemokine CX3CL1 and oncolytic viruses. These approaches have generally yielded positive 
antitumor effects (Braunersreuther et al. 2012; Spaeth et al. 2008). While effective, we 
sought to evaluate a potentially more flexible and potent therapy gene approach using the 
sodium iodide symporter (NIS).  In a previous study using a liver cancer mouse model MSCs 
were transfected with NIS under the control of the broadly unspecific CMV promoter. The 
engineered cells were actively recruited to the tumor and induced a significant antitumor 
effect after application of 131I (Knoop et al. 2011). A similar approach was subsequently 
confirmed in a breast cancer model by Dwyer et al. (Dwyer et al. 2011). 
With its flexibility with regards to diagnostics, imaging and potent therapeutic actions, the NIS 
gene represents an important new dimension in MSC-mediated tumor therapy. Because of 
the potential side effects of MSC recruitment to non-tumor tissues, we examined the potential 
linkage of restricted tissue expression delivered through the use of the RANTES/CCL5 
promoter to NIS-mediated MSC therapy in a model of HCC.  
Upregulation of RANTES/CCL5 by MSCs in tumor stroma is associated with their 
differentiation into cancer-associated fibroblasts. In a murine model of breast cancer, MSCs 
were shown to increase the number of lung metastases. These effects were mediated in part 
by the RANTES/CCL5 produced by the MSCs in the presence of breast cancer cells that 
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acted in a paracrine fashion on cancer cells to enhance their motility, invasion and 
metastasis (Karnoub et al. 2007). Pinilla et al. demonstrated that MSCs derived from human 
adipose tissue (hASCs) produce RANTES/CCL5 in co-culture with breast cancer cells or in 
breast cancer cell conditioned medium, thereby increasing invasion of cancer cells, and 
conclude that RANTES/CCL5 plays a crucial role for tumor invasion in the interplay of tissue 
resident stem cells from fat tissue and breast cancer cells (Pinilla et al. 2009). 
In our study, human MSCs were engineered to express NIS under control of the 
RANTES/CCL5 promoter to more specifically target NIS expression to the tumor stroma, and 
reduce potential side effects linked to MSC recruitment to non-tumor tissues. Initial 
demonstration of tumor stroma-selective RANTES/CCL5 promoter driven expression of 
reporter or therapy genes in engineered MSCs was provided by our own work (Zischek et al., 
2009), where murine MSCs stably transfected with either reporter genes (red fluorescent 
protein (RFP), enhanced green fluorescent protein (eGFP)) or a therapy gene (HSV-Tk) 
driven by the RANTES/CCL5 promoter were used to evaluate the dynamics of expression in 
mice carrying orthotopic, syngeneic pancreatic tumors (Zischek et al. 2009). Application of 
ganciclovir in these animals resulted in a significant reduction in primary tumor growth, as 
well as reduced incidence of metastases (Zischek et al. 2009). The CCL5-based-transgenic 
approach was later directly compared to a Tie2-tumor angiogenesis targeting approach in an 
orthotopic HCC xenograft model (Niess et al. 2011). While both methods showed positive 
results, the results suggested a better outcome when the RANTES/CCL5 promoter was used 
to drive therapeutic transgenes in engineered MSC (Niess et al. 2011; Zischek et al. 2009). 
In contrast to our experiments, most of the previously published studies analyzed MSC 
biodistribution and tumor-specific recruitment by ex vivo analysis of reporter gene 
expression. However, using NIS as a reporter gene allows efficient non-invasive imaging of 
transgene expression by 99mTc-scintigraphy, 123I-scintigraphy or SPECT, and 124I-PET 
imaging, as demonstrated in our study, where tumor homing and engraftment of MSCs was 
non-invasively demonstrated by routine 123I- or 188Re-scintigraphy. This would allow an 
important new dimension in future patient studies, as exact planning of clinical gene therapy 
trials requires a thorough understanding of MSC biodistribution as well as level, duration and 
distribution of transgene expression. Feasibility and efficacy of the NIS gene therapy 
approach using NIS as a theranostic gene has been shown in several former studies by 
different groups including our own (Dwyer et al. 2005a; Dwyer et al. 2005b; Herve et al. 
2008; Kakinuma et al. 2003; Klutz et al. 2009; Li et al. ; Peerlinck et al. 2009; Scholz et al. 
2005; Spitzweg et al. 2007; Spitzweg et al. 2001a; Spitzweg et al. 2000; Spitzweg et al. 
1999; Willhauck et al. 2007b; Willhauck et al. 2008a; Willhauck et al. 2008b; Willhauck et al. 
2008c). 
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Following systemic application of RANTES-NIS-MSCs, 67% of implanted HCC tumors 
showed a tumor-specific 123I and 188Re accumulation as shown by gamma camera imaging 
with a radionuclide accumulation of approx. 6 – 7% ID/g and a biological half-life of 3.7 h, 
which is comparable to the data we had obtained in our previous study using the CMV 
promoter to drive NIS expression in MSCs (7 – 9% ID/g, biological half-life 4 h) (Knoop et al. 
2011). Perchlorate injection prior to radionuclide application and the use of control MSCs 
confirmed NIS-specific radionuclide accumulation. The in vivo imaging data were confirmed 
by ex vivo biodistribution and immunofluorescence analysis, which demonstrated tumor 
stroma-specific accumulation of MSCs in addition to RANTES/CCL5 promoter activation as 
shown by immunohistochemical staining. In contrast, non-target organs like liver or kidney 
showed no NIS, SV40 large T-Ag or RANTES/CCL5 expression. Immunofluorescence 
analysis did reveal an accumulation of MSCs in the spleen, however, these cells did not 
show NIS-specific immunoreactivity. The presence of MSCs in the spleen may result either 
from direct recruitment of the cells (via CCR7) (Von Luttichau et al. 2005), or from filtration of 
the exogenously applied MSCs from the peripheral circulation. Importantly, the lack of 
RANTES/CCL5 promoter driven transgene expression demonstrates enhanced selectivity of 
the approach.  
After three cycles of repetitive RANTES-NIS-MSC injection followed by the application of 131I 
or 188Re, an effective control of tumor growth was seen. This was associated with a 
dramatically improved survival of tumor bearing animals to the end of the nine week 
experiment. By contrast, control animals showed a maximum survival of four weeks. These 
results show a significant improvement over those previously reported by us using the CMV 
promoter to drive NIS expression in the same model system where the mice lived seven 
weeks after NIS-mediated radioiodine therapy (Knoop et al. 2011). 
In the current study we also examined the potential use of 188Re as an alternative therapeutic 
radionuclide to 131I. 188Re is also transported by NIS, but in contrast to 131I, offers the 
possibility of higher energy deposition in the tumor in a shorter period of time due to its 
shorter physical half life and higher energy. Another advantage is that 188Re is less harmful to 
the thyroid, which is primarily caused by the lack of 188Re organification and therefore 
significantly shorter effective half-life of 188Re in the thyroid gland, thereby not only reducing 
radiation damage to the thyroid gland but also increasing tumoral 188Re uptake by the 
elimination or the thyroid “sink” effect (Dadachova et al. 2002). In consideration of the 
scattered MSC biodistribution in the tumor stroma an enhanced therapeutic effect of 188Re 
based on an increase in crossfire effect, due to the longer path length, was expected. In a 
breast cancer mouse model Dadachova and colleagues showed a radiation dose 4.5 times 
higher for 188Re than for 131I resulting in an improved therapeutic efficacy in mice (Dadachova 
et al. 2005). Similarly, in one of our previous studies we have convincingly demonstrated the 
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superior therapeutic effect of 188Re as compared to 131I in a prostate cancer xenograft mouse 
model based on a 4.7-fold higher tumor absorbed dose after application of 188Re as 
compared to 131I (Willhauck et al. 2007b). In the current study, however, therapeutic efficacy 
of 188Re compared to 131I was similar in direct comparison although the tumor absorbed dose 
for 188Re was calculated to be 3 times higher than for 131I (128.7 mGy/MBq vs. 44.3 
mGy/MBq). Based on the survival curve obtained for both radionuclides, it is possible that a 
maximal therapeutic effect was already achieved with 131I treatment. A more detailed titration 
of MSC and radionuclide application in future studies may allow a more precise contrasting 
of the therapeutic consequences of 188Re vs. 131I.   
In addition, since dosimetric calculations are optimized for a homogenous tumoral 
radionuclide uptake and standard dosimetry models not taking into account microdosimetry 
aspects, calculation of tumor absorbed doses after MSC-mediated NIS gene transfer might 
be inaccurate due to inhomogeneous NIS expression and therefore inhomogenous 
radionuclide accumulation in the tumor stroma. 
The mechanism underlying RANTES/CCL5 induction by MSC in tumor milieus is not well 
understood. Osteopontin (OPN), a secreted phosphoprotein that signals through αvβ3 integrin 
and CD44 (Denhardt et al. 1995; Mcallister et al. 2008; Mi et al. 2011) has been shown to 
induce expression of RANTES/CCL5 in MSCs (Mi et al. 2011). EGFR and IGF-1 signalling 
have also been linked to RANTES/CCL5 upregulation by MSCs (Karar and Maity 2009; 
Mascia et al. 2003). A better understanding of this biology may allow the re-engineering of 
the RANTES/CCL5 promoter to optimize tumor specificity and reduce potential expression in 
other tissues (Edelmann et al. 2011; Grone et al. 1999). 
Taken together, our data demonstrate high tumor selectivity of MSC recruitment and 
improved NIS expression driven by the RANTES/CCL5 promoter after systemic MSC 
application in a HCC xenograft model. The resulting biologically targeted, tumor-selective 
radionuclide accumulation was high enough for a therapeutic effect of 131I and 188Re opening 
the exciting prospect of NIS-mediated radionuclide therapy of metastatic cancer using 
engineered MSCs as gene delivery vehicles. 
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4.1 Abstract 
 
The tumor-homing property of mesenchymal stem cells (MSC) has been used for the 
delivery of therapeutic genes into tumor environments. The sodium iodide symporter (NIS) is 
a theranostic gene that allows non-invasive imaging of MSC biodistribution by 123I-
scintigraphy or 124I-PET-imaging as well as potent therapeutic application of 131I or 188Re. 
Expression of the chemokine RANTES/CCL5 is induced by MSCs in the course of tumor 
stroma recruitment and their differentiation into cancer-associated fibroblasts. We recently 
demonstrated effective control of an experimental subcutaneous xenograft model of HCC 
using MSC engineered to express NIS under control of the RANTES promoter (RANTES-
NIS-MSC). Here we contrasted these findings with a more clinically relevant experimental 
orthotopic hepatocellular cancer xenotransplant model established by intrahepatic injection of 
Huh7 cells in nude mice. 
After systemic RANTES-NIS-MSC injection, 123I-scintigraphy and 124I-PET imaging in concert 
with ex vivo biodistribution studies demonstrated MSC recruitment and RANTES/CCL5-
promoter activation in the stroma of hepatic tumors. In contrast, limited MSC-mediated NIS 
expression was detected in healthy liver tissue or non-target organs. The therapeutic effects 
of NIS-mediated radioiodine therapy (55.5 MBq 131I) showed improved survival of tumor 
bearing mice. Immunfluorescence studies also demonstrated markedly reduced proliferation 
and decreased blood vessel density of RANTES-NIS-MSC/131I-treated tumors as compared 
to controls. We show that the relevant host tumor interactions in an orthotopic HCC tumor 
model provide a better environment for the facilitated recruitment and activation of RANTES-
NIS-engineered MSC. These data convincingly demonstrate the enormous potential of MSC-
mediated NIS gene radionuclide therapy in control of hepatocellular carcinoma. 
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4.2 Introduction 
 
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, and the third most 
deadly cancer worldwide. The incidence of HCC is increasing due to the expanding 
prevalence of hepatitis C virus infection. HCC is generally diagnosed at more advanced 
stages, which limits potential therapeutic options (Parkin et al. 2005). If surgical resection of 
the tumor is possible in limited disease, it offers the best prognosis for long-term patient 
survival. However, because of extensive disease, or poor liver function, only a small fraction 
of HCC patients (10-15%) are suitable for surgical resection. This has driven the search for 
novel therapeutic approaches for advanced HCC.  
Solid tumors such as HCC are comprised of tumor cells within a complex stromal matrix that 
include cells linked to angiogenesis, innate and adaptive immune cells, and cancer-
associated fibroblastic (CAF) cells (Yang et al. 2011). Mesenchymal stem cells (MSC) can 
act as progenitors for many of these cell types. In the course of normal tissue repair, MSCs 
become mobilized from various tissue niches and are recruited to sites of tissue damage to 
help effect repair. Tumors are seen by the body as something akin to a chronic wound 
(Aquino et al. 2010; Dvorak 1986), which explains the pronounced tropism that adaptively 
transferred MSCs have for tumor environments, and also provides the biologic basis for use 
of engineered version of MSCs as vehicles for tumor therapy (Dwyer et al. 2011; Knoop et al. 
2011; Knoop et al. 2013; Niess et al. 2011; Zischek et al. 2009).  
However, MSCs can also be recruited to normal tissues as part of tissue homeostasis. Here 
the expression of “therapy” genes could lead to undesired side effects. We have shown that 
tumor-specific therapy gene expression can be enhanced through the use of specific gene 
promoters for driving transgene expression. The promoters derive from genes that are highly 
induced by MSC in tumor tissues, but show less activity in “normal” tissues. Thus the 
transgenes become activated when the MSC come in contact with the tumor environment, 
but are not highly expressed in MSC that may traffic to “non-target” tissues. One such 
promoter was taken from the chemokine CCL5/RANTES gene (Knoop et al. 2013; Niess et 
al. 2011; Zischek et al. 2009). Expression of RANTES is induced by MSCs in the course of 
their recruitment to tumor stroma and subsequent differentiation into CAFs. In addition, 
RANTES/CCL5 expression is associated with increased tumor neovascularization, as well as 
enhanced cancer growth and metastases by autocrine and paracrine activation of tumor cells 
(Karnoub et al. 2007). The RANTES promoter was therefore used to help focus MSC-
transgene induction within the tumor milieu. Early studies of this approach made use of the 
suicide gene Herpes simplex virus thymidine kinase (HSV-TK) as a therapy gene in concert 
with the prodrug ganciclovir. In these studies, murine MSCs were stably transfected with 
either reporter genes (red fluorescence protein (RFP), enhanced green fluorescence protein 
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(eGFP)) or a therapy gene (HSV-TK) driven by the RANTES/CCL5 promoter to evaluate the 
dynamic expression of the transgene in mice carrying orthotopic, syngenic pancreatic 
tumors. Application of ganciclovir in these animals resulted in a significant reduction of 
primary tumor growth as well as reduced incidence of metastases (Zischek et al. 2009). The 
CCL5-based transgenic approach was later directly compared to a Tie2-tumor angiogenesis-
targeting approach in an orthotopic HCC xenograft model (Niess et al. 2011). While the 
results of these preclinical studies were encouraging, the therapeutic effects delivered by 
HSV-TK-based suicide gene therapy were limited to bystander killing, and do not allow 
flexibility of live whole body monitoring. To help address this, these studies were expanded 
through use of the sodium iodide symporter (NIS) as a theranostic gene. The NIS protein is 
responsible for the active uptake of iodide by the thyroid, and as such, forms the basis for the 
diagnostic and therapeutic use of radioiodine in thyroid carcinoma. Use of the NIS gene 
allows both non-invasive in vivo imaging of MSC biodistribution and functional transgene 
expression by 123I-scintigraphy or 124I-PET-imaging and the delivery of a very potent 
therapeutic effect by treatment with 131I or 188Re (Hingorani et al. 2010; Spitzweg and Morris 
2002; Willhauck et al. 2007b).  
We recently demonstrated the effective control of an experimental subcutaneous xenograft 
model of HCC using MSC engineered to express NIS under control of the RANTES 
promoter. Systemic injection of these engineered MSCs led to a significant radioiodine 
accumulation in subcutaneous HCC xenografts resulting in a delay of tumor growth and 
improved survival by therapeutic 131I application (Knoop et al. 2013). These preliminary 
results were very encouraging but did not account for the very important additional 
component of tumor-stromal interaction with the surrounding normal liver tissue environment. 
We describe here an expanded study using an orthotopic HCC tumor model that better 
replicates the biology of the tumor in its natural milieu with associated complicating factors.   
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4.3 Material and methods 
 
Cell culture 
The generation of human MSCs has been described previously (Knoop et al. 2011). The 
human hepatocellular cell line Huh7 (JCRB 0403) was cultured in RPMI (Invitrogen/Life 
technologies, Darmstadt, Germany) supplemented with 10% fetal bovine serum (v/v; PAA) 
and 1% penicillin/streptomycin. The cell lines were maintained at 37°C and 5% CO2 in an 
incubator with 95% humidity. 
 
Plasmid construct and stable transfection of mesenchymal stem cells 
The plasmids used, their construction, and the establishment of stably engineered MSC have 
been described previously (Knoop et al. 2011; Knoop et al. 2013). 
 
Establishment of hepatic HCC xenografts 
The experimental protocol was approved by the regional governmental commission for 
animals (Regierung von Oberbayern). To establish orthotopic tumor models, nude mice were 
anesthetized with 2.5% Isofluran in oxygen and placed on a heated mat in the left lateral 
position. The skin was washed with 70% ethanol and dried using sterile gauze. A 0.5 cm cut 
was made at the right subcostal region extending through the skin and abdominal wall, and 
exposing the lower pole of the liver lobe. A 27-gauge needle was then inserted at the upper 
liver lobe and 50 µl of tumor cell suspension (1x106 cells) in PBS was injected over 15sec. 
The needle was removed and the injection site was gently pressed with a Q-tip to prevent 
bleeding and the reflux of tumor cells into the abdomen or abdominal wall. The abdominal 
wall and the skin were then sutured separately using a Monosyn® 5/0 fiber.  
The mice were pre- and post-treated with Carprofen (5 mg/kg) to minimize wound pain. The 
animals were maintained under specific pathogen-free conditions with access to mouse 
chow and water ad libitum.  
 
MSC application and radionuclide biodistribution studies in vivo 
The eMSC experiments were initiated two weeks after intrahepatic tumor cell injection. 
Pretreatment with the thyroid hormone L-T4 (levothyroxine, (10 µg L-T4/100 g body weight) 
was used to reduce thyroidal NIS expression (Di Cosmo et al. 2009). WT-MSCs or RANTES-
NIS-MSCs were applied via the tail vein at a concentration of 5 x 105 cells/500µl PBS. Two 
groups of mice were established and treated as follows: (a) three i.v. applications of 
RANTES-NIS-MSC in four day intervals (n=20); (b) three i.v. applications of WT-MSC in four 
day intervals (n=7). As an additional control, in a subset of mice injected with RANTES-NIS-
MSC (n=8) the specific NIS-inhibitor sodium-perchlorate (NaClO4, 2 mg per mouse) was 
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injected i.p. 30 min prior to radionuclide administration. 48 h after the last MSC application, 
18.5 MBq 123I was injected i.p. and radionuclide biodistribution was assessed using a gamma 
camera equipped with UXHR collimator (Ecam, Siemens, Germany) as previously described 
(Willhauck et al. 2007b; Willhauck et al. 2008a). Small-animal PET imaging was performed in 
a subgroup of mice treated with RANTES-NIS-MSC (n=7) receiving a dose of 12 MBq 124I. 
PET-Imaging procedure was described previously (Knoop et al. 2011).  
 
Analysis of radionuclide biodistribution ex vivo 
For ex vivo biodistribution studies, mice were injected with RANTES-NIS-MSCs (n=15) or 
WT-MSCs (n=5) as described above followed by i.p. injection of 18.5 MBq 123I. A subset of 
RANTES-NIS-MSC injected mice (n=5) were treated with NaClO4 prior to radionuclide 
administration as an additional control. Four hours after radioiodine injection, mice were 
sacrificed and organs of interest were dissected, weighed and 123I accumulation was 
measured in a gamma counter. Results were reported as percentage of injected dose per 
organ (% ID/organ). 
 
Analysis of NIS mRNA expression using quantitative real-time PCR 
Total RNA was isolated from the liver or other tissues using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s recommendations and quantitative real-
time PCR (qPCR) was performed as described previously (Klutz et al. 2009). 
 
Radionuclide therapy studies in vivo 
Therapeutic applications of MSCs followed by 131I or saline were performed as described 
previously by Knoop et al. (Knoop et al. 2013). The following groups were established: 
RANTES-NIS-MSC + 131I (n=20), RANTES-NIS-MSC + NaCl (n=20) and WT-MSC + 131I 
(n=20). 
By protocol, mice were sacrificed when healthy liver tissue reached less than 20%, or in case 
of weight loss representing more than 10% of starting weight, or when impairment of 
breathing, drinking or eating behavior was observed.  
 
Immunohistochemical analysis 
Immunohistochemical and immunofluorescence staining procedures for the expression of 
NIS and SV40 large T Ag, as well as indirect immunofluorescence analysis, and 
quantification of cellular proliferation (Ki67) and blood vessel density (CD31), were performed 
as described previously (Knoop et al. 2013). 
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Statistical methods 
Statistical significance of in vitro experiments was tested using Student´s t test. Statistical 
significance of the in vivo experiments has been calculated using the Man-Whitney U test.  
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4.4 Results 
 
Radioiodine biodistribution in a hepatic HCC xenograft model after MSC-mediated NIS 
gene transfer 
To assess the potential effect of eMSC-NIS-based therapy in a clinically more relevant 
model, an orthotopic tumor model of hepatic HCC xenograft was used. In these experiments 
the human hepatocellular carcinoma cell line Huh7 was injected into the right liver lobe of 
immune-compromised mice, leading to the establishment of solid intrahepatic xenografts 
after five weeks. MSC treatment was initiated three weeks after intrahepatic tumor cell 
injection. RANTES-NIS-MSCs or WT-MSCs were injected via the tail vein 3-times in 4-day-
intervalls. 48 hours after the last MSC injection, 18.5 MBq 123I were applied to determine the 
iodide accumulation in the hepatic xenografts by gamma camera imaging. Three hours after 
123I injection, enhanced iodide uptake activity was detected in the right liver lobe, which 
resulted in a maximum uptake of 16.5 ± 1 % ID/g with a biological half-life of 3.4 hours, and a 
tumor absorbed dose of 96 mGy/MBq (Fig. 1a, d). In contrast, control mice with intrahepatic 
Huh7 xenografts treated with WT-MSCs showed no iodide uptake after radioiodine 
application (Fig. 1c). Treatment of a subgroup of the RANTES-NIS-MSC-injected mice with 
the competitive NIS inhibitor perchlorate 30min prior to radioiodine injection showed a 
complete blockade of radionuclide accumulation in intrahepatic Huh7 xenografts as well as in 
physiologically NIS-expressing organs including the thyroid gland and stomach. The high 
iodide accumulation in the bladder results from renal excretion of the radionuclides (Fig. 1b). 
To improve the resolution of radioiodine uptake in the liver area, and to more clearly 
differentiate between hepatic and gastric iodide accumulation, additional PET imaging 
studies were performed using 124I. Three-dimensional data were subsequently generated 
using iterative reconstructions of list mode data (0-40min), which provided better anatomical 
definition. 48 hours after the last RANTES-NIS-MSC administration, 12 MBq 124I were applied 
and selective iodide accumulation was detected in intrahepatic Huh7 xenografts three hours 
after 124I application (Fig. 1 e – g). In 70% of RANTES-NIS-MSC-treated mice a maximum 
uptake of 13.6 ± 1.9 % ID/g was measured in intrahepatic Huh7 xenografts.  
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Figure 1 Radioiodine accumulation in an hepatic Huh7 xenograft mouse model following 
systemic RANTES-NIS-MSC administration. Systemic injection with RANTES-NIS-MSCs resulted in 
enhanced iodide accumulation in livers of mice harbouring intrahepatic HCC tumors three hours after 
radionuclide administration as shown by 123I-gamma-camer imaging (a) and small animal 124I-PET 
imaging (e – f), which was completely blocked upon treatment with the NIS-specific inhibitor (NaClO4) 
(b). Mice systemically injected with WT-MSC showed no tumoral iodide uptake (c). Iodide uptake 
activity resulted in a maximum uptake of 16.5 ± 1 % ID/g with a biological half-life of 3.4 hours and a 
tumor absorbed dose of 96 mGy/MBq (d). 
 
 
Chapter 3 
66 
 
Ex vivo radioiodine biodistribution studies 
In addition to the imaging studies, quantitative ex vivo biodistribution studies were performed 
four hours after injection of 18.5 MBq 123I. In hepatic Huh7 xenograft-bearing mice, an iodide 
uptake of 6.9 ± 1.8 % ID/g tumor tissue was found, supporting the results of the imaging 
studies. In addition, no iodide uptake activity was measured in non-target organs, or tumors 
from mice injected with WT-MSCs. Mice injected with RANTES-NIS-MSCs and treated with 
the competitive NIS inhibitor perchlorate showed no iodide uptake activity in tumors (Fig. 2) 
as well as thyroid gland and stomach (data not shown). 
 
 
Figure 2 Ex vivo radioiodine biodistribution studies. Ex vivo biodistribution studies four hours after 
18.5 MBq 123I injection revealed an iodide uptake of 6.9 ± 1.8 % ID/g in intrahepatic HCC tumors of 
mice treated with RANTES-NIS-MSC, whereas no significant radioiodine uptake was measured in 
non-target organs, after pretreatment with perchlorate or after systemic injection of WT-MSC. Results 
are reported as percent of injected dose per g ± SD. 
 
 
Analysis of NIS protein expression by indirect immunofluorescence 
The distribution of MSCs in tumors was determined in more detail by immunofluorescence 
staining using NIS- and SV40 large T Ag- specific antibodies. SV40 large T Ag was used to 
immortalize the MSCs and could thus can be used as a target to assess biodistribution of 
engineered MSCs, while human NIS-specific antibodies allowed the determination of 
RANTES promote-induced NIS transgene expression. Paraffin-embedded tissues from liver 
were processed for immunofluorescence staining using both sets of antibodies. In 
intrahepatic HCC tumors of mice treated with RANTES-NIS-MSCs, NIS-specific 
immunoreactivity was detected and was confined to the tumor (Fig. 3a), while no NIS-specific 
staining was seen in the surrounding normal liver tissue. This biodistribution pattern was 
confirmed by SV40 large T Ag-specific staining demonstrating the presence of eMSCs in 
intrahepatic tumor tissue (Fig. 3b) and not into normal liver tissue. Systemic injection of WT-
MSCs showed no NIS-specific immunoreactivity in intrahepatic HCC tumors (Fig. 3c) or in 
normal liver tissue; however, SV40 large T Ag staining still demonstrated active MSC 
Chapter 3 
67 
 
recruitment into intrahepatic tumors, thus supporting tumor-selective eMSC recruitment (Fig. 
3d).  
 
 
Figure 3 Analysis of NIS protein expression after systemic RANTES-NIS-MSC injection by 
indirect immunofluorescence. Hepatic Huh7 xenografts in RANTES-NIS-MSC-treated mice showed 
NIS-specific immune-reactivity (a), which was similar to the localization of the MSC-specific SV40 
large T Ag staining (b). Systemic injection of WT-MSC resulted in no NIS-specific immuno reactivity 
(c), despite a strong SV40 large T Ag staining (d), confirming specific MSC recruitment in to the tumor. 
 
 
Therapeutic application of 131I resulted in improved survival of mice harboring hepatic 
Huh7 xenografts 
The therapeutic effect of 131I was assessed in mice carrying intrahepatic HCC tumors using 
the therapy regime optimized in previous studies (Knoop et al. 2013). The protocol is based 
on three cycles of systemic eMSC injecetions followed by 131I (Fig. 4a). After systemic 
injection of RANTES-NIS-MSCs followed by 131I injection a significantly improved survival of 
up to four weeks was observed as compared to control groups of mice injected with 
RANTES-NIS-MSC followed by saline application, or mice treated with WT-MSC followed by 
the application of 131I (Fig. 4a).  
One week after the last radioiodine injection, a subset of mice was sacrificed, livers were 
removed and characterized by immunofluorescence analysis for cellular proliferation (Ki67, 
green) and blood vessel density (CD31, red) markers. Striking differences were observed 
between therapy and control groups (Fig. 4 b – d). Mice treated with RANTES-NIS-MSCs 
followed by 131I showed decreased proliferation (Ki67: 37.38 ± 5.85 %) (Fig. 4f) and blood 
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vessel density (CD31: 3.43 ± 0.61 %) (Fig. 4e), whereas control mice treated with RANTES-
NIS-MSC followed by saline or mice treated with WT-MSC followed by 131I application 
revealed high blood vessel density (CD31) (RANTES-NIS-MSC + NaCl: 6.23 ± 0.69 %; WT-
MSC + 131I: 7.15 ± 1.2 %) (Fig. 4e, f) and high levels of proliferation (Ki67) (RANTES-NIS-
MSC + NaCl: 66.9 ± 10.65 %; WT-MSC + 131I: 61.18 ± 10.22 %) (Fig. 4e, f). At the end of the 
observation period, the remaining animals were sacrificed and analyzed, still showing 
reduced proliferation and blood vessel density in the therapy group albeit to a lower extent 
(RANTES-NIS-MSC + 131I: Ki67: 54.9 ± 12.1 %, CD31: 4.3 + 1.1 %), as compared to control 
groups (RANTES-NIS-MSC + NaCl: Ki67: 76.5 ± 11.2 %, CD31: 6.2 ±1.4 %; WT-MSC + 131I: 
Ki67: 72.42 ± 10.8 %, CD31: 6.3 ± 1.3 %) (data not shown). 
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Figure 4 Therapeutic application of 131I resulted in an improved survival of mice harbouring 
intrahepatic Huh7 xenografts. Two groups of mice were established receiving 55.5 MBq 131I after the 
final of three RANTES-NIS-MSC or WT-MSC applications in two-day-intervals. This cycle was 
repeated once 24 hours after the last radioiodine application. 24 hours after these two treatment 
cycles, one additional MSC injection was administered followed by a third 131I injection 48 hours later. 
A further control group received RANTES-NIS-MSCs and saline. Therapeutic application of 131I after 
i.v. injection of RANTES-NIS-MSCs resulted in significantly improved survival as compared to the 
control groups (a). Immunofluorescence analyses of intrahepatic HCC tumors using a Ki67-specific 
antibody (green, labelling proliferating cells) and an antibody against CD31 (red, labelling blood 
vessels) showed striking differences in tumor cell proliferation and blood vessel density in hepatic 
HCC tumors of mice treated with RANTES-NIS-MSCs and 131I (b), which was significantly reduced 
(Ki67: 37.38 ± 5.85 %; CD31: 3.43 ± 0.61 % (e, f)) as compared to the control groups of mice treated 
with RANTES-NIS-MSC and saline (c) (CD31: 6.23 ± 0.69 %; Ki67: 66.9 ± 10.65 % (e, f)) or WT-MSC 
and 131I (d) (CD31: 7.15 ± 1.2 %; Ki67: 61.18 ± 10,22 % (e, f)). Slides were counterstained with 
Hoechst nuclear stain. Magnification x200. 
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4.5 Discussion 
 
Gene therapy represents a promising and active field of cancer therapy. Although previous 
studies have yielded some exciting results in animals models, clinical trials have shown 
limited antitumor efficacy, at least in part due to insufficient gene delivery to tumor sites 
(Komarova et al. 2006). Introducing a therapeutic transgene into mesenchymal stem cells 
(MSC) represents an emerging cell-based delivery strategy (Studeny et al. 2002). The 
rationale for using bone marrow-derived MSCs as delivery vehicles to tumors is based on the 
concept that MSCs are actively recruited from the blood into tissues in response to injury 
(Aquino et al. 2010). As the microenvironment of a solid tumor is similar to that of an injured 
tissue, solid tumors provide a permissive environment for the efficient engraftment of 
exogenously applied MSCs (Kidd et al. 2009; Nakamizo et al. 2005). 
We and others have previously shown the clinical potential of engineered MSC as therapy 
vehicles for the treatment of various tumor models. In models of pancreatic, breast and liver 
cancer, we have applied MSCs transduced with HSV-TK and demonstrated active tumor 
stroma-selective recruitment of MSCs that significantly reduced tumor growth and 
metastasizing potential after treatment with ganciclovir (Conrad et al. 2011; Niess et al. 2011; 
Zischek et al. 2009).   
Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumors 
worldwide. Because of their easy establishment, most interventional studies published to 
date have relied on subcutaneous HCC xenograft models. By contrast, orthotopic 
implantation of liver tumors allows the important inclusion of relevant host tumor-interactions 
leading to a clinically more relevant microenvironment and thus allows more insight into the 
potential effect of therapeutic approaches.  
An important step in translational medicine is the fusion of diagnosis and therapy, which 
allows for the refinement of diagnostic and therapeutic procedures for disease evaluation. 
The use of such a “theranostic” approach has become increasingly important in pre-clinical 
and clinical research, in particular in gene therapy approaches with the development of a 
series of new viral and non-viral vectors and an increasing repertoire of therapy genes.  
A series of studies by different research groups including our own have shown the feasibility 
and efficacy of the use of NIS as a theranostic gene (Dwyer et al. 2011; Grunwald et al. 
2013c; Klutz et al. 2009; Knoop et al. 2013; Spitzweg et al. 2000). NIS serves as a reporter 
gene allowing efficient non-invasive imaging of vector biodistribution and transgene 
expression by 123I-scintigraphy or SPECT and 124I-PET imaging and therefore provides a 
novel method for repetitive in vivo monitoring of tumor homing and engraftment of MSCs 
(Dwyer et al. 2011; Knoop et al. 2011; Knoop et al. 2013), which represents an essential 
prerequisite for the exact planning of clinical gene therapy trails. 
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After proof-of-principle of the MSC-mediated NIS gene transfer approach in subcutaneous 
xenografts in our earlier studies (Knoop et al. 2011; Knoop et al. 2013), the next crucial step 
was to study the potential of this approach in a clinically more relevant tumor model. 
Subcutaneous xenografts are simple to perform; they show low intra-procedure mortality and 
allow easy visualization and monitoring of tumor growth. However, it does not allow for the 
inclusion of specific effects that derive from the host-tissue environment. A capsule is often 
formed around subcutaneous tumors and metastases rarely occur (Fidler 1990; Nakajima et 
al. 1990; Yang et al. 2011). The biochemical milieu and blood supply are also different in the 
skin than in the source organ. This is especially true in the case of liver tumors, where a 
portal vein system and drug-detoxifying enzymes exist. In this context, the response to 
chemotherapeutic agents has been shown to vary depending on whether the tumor is ectopic 
or orthotopic (Wilmanns et al. 1992; Yao et al. 2003). In one of our earlier studies, Niess et 
al. generated an intrahepatic HCC xenograft model in mice by intrahepatic injection of Huh7 
HCC cells (Niess et al. 2011). After systemic injection of MSCs either transfected with a red 
fluorescence protein (RFP) gene or a HSV-TK gene under the control of the RANTES 
promoter, tumor-specific recruitment was monitored ex vivo by detection of RFP. Therapeutic 
potential was demonstrated by the use of RANTES/HSV-TK transfected MSCs and 
additional treatment with ganciclovir which resulted in an significantly reduced tumor growth 
(Niess et al. 2011).  
In the present study we also used the orthotopic HCC xenograft model for evaluation of the 
MSC-mediated NIS gene delivery concept using the RANTES promoter to drive tumor 
stroma-selective NIS expression. After systemic injection of RANTES-NIS-MSCs, 123I-
gamma-camera and 124I-PET imaging demonstrated tumor stroma-targeted MSC recruitment 
and transgene activation by significant iodide uptake activity in the intrahepatic HCC 
xengrafts. The tumor-specific iodide uptake activity was further confirmed by ex vivo 
biodistribution studies. Interestingly, the iodide uptake activity observed in the intrahepatic 
xenografts (max. uptake 16.5 % ID/g 123I) was even higher than we had reported previously 
in subcutaneous tumors (max. uptake 6.5 % ID/g 123I) (Knoop et al. 2013), which could be the 
result of the more representative tumor stroma milieu in the liver with enhanced stromal 
growth as compared to the subcutaneous milieu leading to a more active MSC recruitment 
and engraftment. This also resulted in doubling of the tumor-absorbed dose that was 
achieved in the intrahepatic HCC model (96 mGy/MBq) as compared to the subcutaneous 
tumor model (44.3 mGy/MBq) (Knoop et al. 2013). Three cycles of repetitive RANTES-NIS-
MSC injection followed by the application of 131I resulted in a dramatically improved survival 
of tumor-bearing mice up to 9 weeks as compared to 5 weeks in the control groups.  
Taken together, in the current study we were able to translate our previous findings of MSC-
mediated systemic NIS gene delivery in subcutaneous liver cancer xenografts into a clinically 
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more relevant mouse model of intrahepatic liver cancer xenografts. Non-invasive 123I-
scintigraphy and 124I-PET imaging demonstrated remarkable tumor-selectivity of MSC 
recruitment and NIS expression driven by the tumor stroma-specific RANTES/CCL5 
promoter after systemic MSC application. The resulting biologically targeted, tumor-selective 
radionuclide accumulation was high enough for a significant therapeutic effect of 131I. These 
data convincingly demonstrate the enormous potential of MSC-mediated NIS gene 
radionuclide therapy of advanced and /or metastatic cancer. 
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5.1 Translational Relevance 
 
Engineered mesenchymal stem cells are currently being tested clinically as therapy vehicles 
for solid tumors. Most preclinical data generated to date has focused on primary tumors. The 
sodium iodide symporter (NIS) represents one of the oldest and most successful targets for 
molecular imaging and targeted radionuclide therapy by the application of radioiodine for the 
management of thyroid cancer. Cloning of the NIS gene allowed investigation of its 
expression and regulation in thyroidal and non-thyroidal tissues paving the way for a novel 
cytoreductive gene therapy. In previous studies we demonstrated the potential of 
mesenchymal stem cells (MSC) as tumor-selective gene delivery vehicles based on their 
homing to the tumor stroma. This translational study is the first preclinical trial to demonstrate 
the potential of MSC-mediated NIS gene delivery in a hepatic colon cancer metastases 
model, as shown by NIS-targeted radionuclide imaging and a therapeutic effect of 
radioiodine, resulting in an improved survival. 
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5.2 Abstract 
 
The tumor-homing property of mesenchymal stem cells (MSCs) allows targeted delivery of 
therapeutic genes into the tumor microenvironment. The application of the sodium iodide 
symporter (NIS) as a theranostic gene allows non-invasive imaging of MSC biodistribution 
and transgene expression before therapeutic radioiodine application. We have previously 
shown that linking therapeutic transgene expression to induction of the chemokine 
CCL5/RANTES allows a more focused expression within primary tumors as the adoptively 
transferred MSC develop CAF-like characteristics. While RANTES/CCL5-NIS-targeting has 
shown efficacy in the treatment of primary tumors, it was not clear if it would also be effective 
in controlling the growth of metastatic disease.   
In the present study, we investigated the biodistribution and tumor recruitment of MSCs 
engineered to express the NIS gene under control of the RANTES/CCL5 promoter 
(RANTES-NIS-MSC) in a colon cancer liver metastasis mouse model established by 
intrasplenic injection of the human colon cancer cell line LS174t. 
Five days after intrasplenic tumor cell injection RANTES-NIS-MSCs were injected 
intravenously three times followed by 123I-scintigraphy and 124I-PET imaging. Results show 
selective MSC recruitment and RANTES/CCL5-promoter activation in the stroma of liver 
metastases as evidenced by tumor-selective iodide accumulation, immunohistochemistry 
and real-time PCR. Therapeutic application of 131I in RANTES-NIS-MSC-treated mice 
resulted in a significant delay in tumor growth and improved overall survival. 
These results convincingly demonstrate selective recruitment and activation of RANTES-
NIS-MSC into liver metastases of colon cancer allowing tumor-specific iodide accumulation. 
This novel gene therapy approach opens the prospect of NIS-mediated radionuclide therapy 
of metastatic cancer after MSC-mediated gene delivery. 
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5.3 Introduction 
 
Effective control of metastatic disease represents a central challenge in the treatment of solid 
tumors. Colorectal cancer is the third most common cancer world-wide, with the liver being 
the most common site of metastases. While the prognosis of resectable colorectal liver 
metastases was improved in the recent years, 5-year survival rates after resection are still 
not higher than 25% to 40%, and survival rates have remained poor for unresectable disease 
(Siegel et al. 2013). 
An emerging tumor therapy approach is based on the use of adoptively transferred 
mesenchymal stem cells (MSCs) as vehicles engineered to express specific reporter and/or 
therapy genes (eMSC). This approach makes use of the innate ability of MSCs to migrate to 
damaged tissue in the course of tissue repair (Aquino et al. 2010). Tumors are seen by the 
body as chronic, never healing wounds that drive continuous tissue remodeling thus 
providing the basis for the marked tumor tropism of MSCs (Dvorak 1986). We and others 
have harnessed this biology by using eMSC to deliver anti-cancer gene products deep into 
tumor stromal environments (Conrad et al. 2007; Conrad et al. 2011; Conrad et al. 2009; 
Knoop et al. 2011; Knoop et al. 2013; Niess et al. 2011; Zischek et al. 2009). Adoptively 
transferred MSCs are actively recruited to growing tumors where they contribute to the 
formation of the “benign” stromal compartment containing a variety of distinct cell types, 
including endothelial cells, smooth muscle cells, and pericytes/carcinoma-associated 
fibroblasts that provide important support for the growth of solid tumors. However, MSCs also 
contribute to normal tissue homeostasis and therefore also migrate to non-tumor 
environments under these conditions. In order to reduce potential side effects of transgene 
expression in non-tumor-associated tissues, the therapeutic utility of eMSCs has been 
enhanced by the use of tumor stroma-specific gene promoters linked to unique differentiation 
pathways activated as MSC respond to tumor microenvironments. For example, the Tie2 
promoter/enhancer is activated as MSC respond to angiogenic signals within tumor 
environments, but is not strongly activated in normal tissue settings (Niess et al. 2011; 
Zacharek et al. 2007). MSC engineered to express the suicide gene herpes simplex virus 
thymidine kinase (HSV-TK) under control of the Tie2 promoter/enhancer showed selective 
expression of transgenes following systemic injection of the eMSC into mice with growing 
breast, pancreatic or liver tumors. Further, the TK gene product generated in the tumor 
environment, in combination with application of the prodrug ganciclovir resulted in a 
significant reduction in primary tumor growth, as well as prolongation of life (Conrad et al. 
2011; Niess et al. 2011). While this approach was effective in targeting large primary tumors, 
the Tie2-based strategy showed low efficacy in the treatment of tumor metastases. To 
address this, an alternative targeting approach was developed with the use of the 
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RANTES/CCL5 promoter to drive transgene expression in MSCs. In the course of 
differentiation into carcinoma-associated fibroblasts (CAFs), a key cell type in the 
establishment and progression of solid tumors, MSCs induce expression of the chemokine 
RANTES (Karnoub et al. 2007; Zlotnik and Yoshie 2000). eMSC engineered to express HSV-
TK under control of the RANTES promoter in concert with GCV treatment led not only to a 
significant reduction in the growth of primary pancreatic carcinoma, but also dramatically 
reduced incidence of metastases in a pancreatic cancer model (Zischek et al. 2009).  
In order to enhance potential therapeutic benefit of MSC-mediated gene therapy, a more 
aggressive therapy gene was developed. The sodium iodide symporter (NIS) protein is 
responsible for the active uptake of iodide from the blood into the thyroid gland, and as such, 
forms the molecular basis for the diagnostic and therapeutic use of radioiodine, that has 
been used for almost 70 years in the management of differentiated thyroid cancer (Spitzweg 
and Morris 2002). One of the major advantages of NIS as a therapy gene is not only the 
extensive experience that clinicians already have with NIS-mediated radioiodine therapy, but 
also its dual function as therapy as well reporter gene (Spitzweg and Morris 2002);(Spitzweg 
2009);(Baril et al. ; Hingorani et al. 2010; Penheiter et al. 2012a; Penheiter et al. 2012b). 
MSCs engineered to express NIS can be monitored by whole body imaging using 123I-
scintigraphy/SPECT or 124I- and 18F-TFB-PET allowing direct, non-invasive in vivo imaging of 
MSC biodistribution and functional transgene expression (Dingli et al. 2003a; Groot-Wassink 
et al. 2004; Jauregui-Osoro et al. 2010). Importantly, a robust therapeutic effect can be 
delivered through 131I or 188Re application resulting in a potentially stronger therapeutic effect 
than that seen with standard suicide genes (Knoop et al. 2011; Knoop et al. 2013). In the 
present study, the efficacy of RANTES-based eMSC targeting of NIS expression was 
evaluated in an experimental mouse model of colon cancer liver metastases. 
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5.4 Material and methods 
 
Cell culture 
The establishment and characterization of MSCs has been described previously (Knoop et 
al. 2011). The human colon carcinoma cell line LS174t (ATCC CCL188) was cultured in 
RPMI (Invitrogen/Life technologies, Darmstadt, Germany) supplemented with 10% fetal 
bovine serum (v/v; PAA) and 1% penicillin/streptomycin. The cell lines were maintained at 
37°C and 5% CO2 in an incubator with 95% humidity. 
 
Plasmid construct and stable transfection of mesenchymal stem cells 
Plasmids and their synthesis as well as the establishment of stably transfected cell lines 
have been described previously (Knoop et al. 2011; Knoop et al. 2013). 
 
Establishment of a hepatic colon cancer metastases mouse model 
The experimental protocol was approved by the regional governmental commission for 
animals (Regierung von Oberbayern). Fully anesthetized female CD-1 nu/nu mice (Charles 
River, Sulzfeld, Germany) were placed in the right lateral position. After the skin was washed 
(70% ethanol), a 0.5 cm cut was made at the left subcostal region exposing the lower pole of 
the spleen. A 27-gauge needle was then inserted at the upper splenic pole and 50 µl of tumor 
cell suspension (1x106 cells in 1xPBS) was injected. The abdominal wall and the skin were 
then sutured separately using a Monosyn® 5/0 fiber. 48 h later the abdominal wall was re-
opened at the same site and a splenectomy was performed, followed by suturing of the 
abdominal wall and the skin. Mice were pre- and post-treated with Carprofen (5 mg/kg) to 
minimize wound pain. The induction of liver metastases with this technique was highly 
reproducible; histological liver studies showed that 90% of injected mice developed 
disseminated liver metastases. Animals were maintained under specific pathogen-free 
conditions with access to mouse chow and water ad libitum.  
 
MSC application and radionuclide biodistribution studies in vivo 
The eMSC applications were initiated five days after intrasplenic tumor cell injection, before 
metastatic disease was visible. Pretreatment with thyroid hormone L-T4 (levothyroxine) 
effectively downregulates thyroidal NIS expression, the treatment schedule used was based 
in part on the study by Di Cosmo et al. using a supraphysiological LT-4 dose (10 µg L-T4/100 
g body weight) (Di Cosmo et al. 2009). Mice weighed between 20 – 25 g, and therefore a 
dose of 2 µg L-T4/mouse/d was applied. WT-MSCs or RANTES-NIS-MSCs were applied via 
the tail vein at 5 x 105 cells/500µl PBS. Two groups of mice were established and treated as 
follows: (a) three intravenous (i.v.) applications of RANTES-NIS-MSC in three day intervals 
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(n=22); (b) three i.v. applications of WT-MSC in three day intervals (n=7). As an additional 
control, in a subset of mice injected with RANTES-NIS-MSC (n=7) the specific NIS-inhibitor 
sodium-perchlorate (NaClO4, 2 mg per mouse) was injected intraperitoneally (i.p.) 30 min 
prior to radionuclide administration. 48 h after the last MSC application, 18.5 MBq 123I was 
injected i.p. and radionuclide biodistribution was assessed using a gamma camera equipped 
with UXHR collimator (Ecam, Siemens, Germany) as described previously (Willhauck et al. 
2007b; Willhauck et al. 2008a). Small-animal PET imaging was performed in a subgroup of 
mice treated with RANTES-NIS-MSC (n=8) receiving a dose of 12 MBq 124I 48 h after the last 
MSC application. The PET-imaging procedure was described previously (Knoop et al. 2011).  
 
Analysis of radioiodine biodistribution ex vivo 
For ex vivo biodistribution studies, mice were injected with RANTES-NIS-MSCs (n=15) or 
WT-MSCs (n=5) as described above followed by i.p. injection of 18.5 MBq 123I. A subset of 
RANTES-NIS-MSC injected mice (n=5) were treated with NaClO4 prior to radionuclide 
administration as an additional control. Three hours after radioiodine injection, mice were 
sacrificed and organs of interest were dissected, weighed and 123I accumulation was 
measured in a gamma counter. Results were reported as percentage of injected dose per 
organ (% ID/organ). 
 
Analysis of NIS mRNA expression using quantitative real-time PCR 
Total RNA was isolated from the liver and other tissues using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s recommendations and quantitative real-
time PCR (qPCR) was performed as described previously (Klutz et al. 2009). 
 
Radioiodine (131I) therapy studies in vivo 
Following a 10-day L-T4 pretreatment as outlined above, two groups of mice were 
established that each received 55.5 MBq 131I (sodium iodide; GE Healthcare Buchler GmbH, 
Braunschweig, Germany) 48 h after three RANTES-NIS-MSC (RANTES-NIS-MSC + 131I, 
n=15) or WT-MSC (WT-MSC + 131I, n=15) applications given in two-day-intervals (each 5 x 
105 cells/500 µl PBS). 24 h later we applied two more rounds of two MSC (5 x 105 cells) 
injections (in two-day-intervals) followed by 55.5 MBq 131I 48 h later (Fig. 5A). As control, one 
further group of mice was treated with saline instead of radionuclides after injection of 
RANTES-NIS-MSC (n=15). By protocol, mice were sacrificed when healthy liver tissue 
reached less than 20%, or in case of weight loss of more than 10% of initial weight, or when 
impairment of breathing, drinking or eating behavior was observed. 
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Magnetic Resonance Imaging (MRI) 
For MRI examinations, animals were anaesthetized by i.p. injections of ketamine (Inresa 
Arzneimittel, Freiburg, Germany) 100mg/kg body weight) and xylazine (Bayer, Leverkusen, 
Germany) 10mg/kg body weight) and a 27-gauge tail vein catheter was placed for 
subsequent contrast media administration. MRI was performed on a clinical 3 Tesla system 
(Magnetom Skyra, Siemens Healthcare, Erlangen, Germany) with animals in prone position, 
using a clinical wrist coil (Siemens Healthcare, Erlangen, Germany). MRI acquisition was 
performed using a brief imaging protocol with T1 sequences in axial and coronal view for 
optimal delineation of intrahepatic tumor manifestations. T1-weighted FLASH3D sequences 
were acquired pre-contrast and after a standardized i.v. manual bolus injection of 100 µl of 
Gadolinium-based contrast medium (Primovist®, Bayer Healthcare AG, Berlin, Germany). 
Sequence details were TR=5.74 ms; TE=2.26 ms; ST=1 mm; α=10°; matrix size 416×416; 
reconstructed matrix 832×832; field of view 150×150 mm²; spatial resolution 0.18×0.18×1 
mm³; 80 slices; acquisition time 142 sec. 
  
Immunohistochemical analysis 
Immunohistochemical and immunofluorescence staining procedures for the expression of 
NIS and SV40 large T Ag as well as quantification of cellular proliferation (Ki67) and blood 
vessel density (CD31) were performed as described previously (Knoop et al. 2013). 
 
Statistical methods 
Statistical significance of in vitro experiments was tested using Student´s t test. Statistical 
significance of the in vivo experiments has been calculated using the Man-Whitney U test.  
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5.5 Results 
 
Radioiodine in vivo imaging studies 
To study the potential utility of RANTES driven NIS-based eMSC treatment of colon cancer 
liver metastases, human colon cancer cells LS174t were injected into the spleen of nude 
mice followed by splenectomy 48 hours later. In 90% of mice, 14 days thereafter multifocal 
colon cancer metastases were routinely detected in the liver. To evaluate the ability of eMSC 
to target early stages of liver metastases, five days after intrasplenic tumor cell injection - 
before visible metastases developed - eMSCs were injected via the tail (see Materials and 
Methods). The biodistribution of eMSC expressing NIS under control of the RANTES 
promoter was then determined by 123I-scintigraphy after injection of 18.5 MBq 123I. Enhanced 
iodide uptake activity was detected in the liver area by gamma camera imaging two hours 
after 18.5 MBq 123I injection (Fig. 1a), which resulted in a maximum uptake of 12.1 ± 2.6 % 
ID/g with a biological half-life of 2.9 h, and a tumor absorbed dose of 63.2 mGy/MBq (Fig. 
1g). In contrast, after injection of WT-MSC no liver-specific iodide accumulation was detected 
(Fig. 1c). To further demonstrate NIS-specificity of iodide uptake in the liver region, a subset 
of RANTES-NIS-MSC-treated mice received NaClO4 30 min prior to radioiodine injection, 
which resulted in a complete blockade of iodide accumulation in liver metastases, in addition 
to thyroid gland and stomach (Fig. 1b), which represent physiologically NIS-expressing 
organs. The high iodide accumulation seen in the bladder is a result of renal iodide excretion. 
To improve the resolution of radioiodine uptake in the liver area, and to more clearly 
differentiate between hepatic and gastric iodide accumulation, additional PET imaging 
studies were performed using 124I. Three-dimensional data were subsequently generated 
using iterative reconstructions of list mode data (0-40min), which provided better anatomical 
definition. 48 hours after the last RANTES-NIS-MSC administration, 12 MBq 124I were applied 
and selective iodide accumulation was detected in single metastases three hours after 124I 
application (Fig. 1d – f). In 70% of RANTES-NIS-MSC-treated mice a maximum uptake of 
16.2 ± 3.5 % ID/g was measured in single nodules. 
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Figure 1 Radioiodine accumulation in liver metastases following systemic RANTES-NIS-MSC 
administration. Systemic injection with RANTES-NIS-MSCs resulted in enhanced iodide 
accumulation in livers of mice harbouring colon cancer metastases two hours after radionuclide 
administration as shown by 123I-gamma-camera imaging (a) and small animal 124I-PET imaging (d – f), 
which was completely blocked upon treatment with the NIS-specific inhibitor NaClO4 (b). I.v. injection 
of WT-MSCs did not result in enhanced radioiodine accumulation in the liver region (c). Iodide uptake 
activity resulted in a maximum uptake of 12.1 ± 2.6 % ID/g with a biological half-live of 2.9 hours and a 
tumor absorbed dose of 63.2 mGy/MBq (g). 
 
 
Ex vivo radioiodine biodistribution study 
To complement the imaging studies, ex vivo gamma counter analysis of radioiodine 
biodistribution was performed which confirmed increased iodide uptake (approximately 6.1 ± 
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1.1 % ID/g) in the liver of RANTES-NIS-MSC-treated mice 3 hours after 123I injection (Fig. 2). 
In non-target organs, or in organs of WT-MSC-injected mice, only background levels of 
iodide uptake were detected (Fig. 2). In additional control mice injected with RANTES-NIS-
MSC, administration of the competitive inhibitor perchlorate resulted in a blockade of iodide 
uptake in liver (Fig. 2) as well as thyroid gland and stomach (data not shown). 
 
 
Figure 2 Ex vivo biodistribution studies. Ex vivo biodistribution studies 3 hours after injection of 
18.5 MBq 123I revealed a hepatic iodide uptake of approx. 6.1 ± 1.1% ID/g, while no significant 
radioiodine uptake was measured in non-target organs, after pretreatment with perchlorate, or after 
systemic injection of WT-MSCs. Results are reported as percent of injected dose per g ±SD. 
 
 
Immunohistochemical analysis of eMSC / transgene biodistribution  
eMSC biodistribution was further analyzed ex vivo using immunohistochemistry. SV40 large 
T Ag was used to immortalize the MSCs and could thus be used as target to assess the 
biodistribution of eMSCs, while human NIS-specific antibodies allowed the determination of 
RANTES promoter-induced NIS transgene expression. Paraffin-embedded tissues from liver 
and additional “non-target” organs (lung, kidneys) were processed for immunohistochemical 
staining using both sets of antibodies. In liver metastases of mice treated with RANTES-NIS-
MSCs, NIS-specific immunoreactivity was confined to metastatic nodules, and no NIS-
specific staining was seen in the surrounding normal liver tissue (Fig. 3a). This biodistribution 
pattern was confirmed by SV40 large T Ag-specific staining which confirmed the presence of 
eMSCs in the metastases and not into the normal liver tissue (Fig. 3c). Systemic injection of 
WT-MSCs in mice harboring colon cancer liver metastases showed no NIS-specific 
immunoreactivity in metastases or in normal liver tissue (Fig. 3b); However, SV40 large T Ag 
staining still demonstrated active WT-MSC recruitment into the metastatic nodules (Fig. 3d), 
thus supporting tumor-selective eMSC recruitment. Immunofluorescence analysis confirmed 
co-localization of NIS- and SV40 large T Ag staining in the stroma of liver metastases of 
tumor-bearing mice after injection of RANTES-NIS-MSC (Fig. 3e – g). 
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In non-target organs such as lung or kidney, no NIS-specific or SV40 large T Ag-specific 
staining was detected in mice treated with RANTES-NIS-MSCs (Fig. 3h – k). 
 
 
Figure 3 Immunohistological analysis of eMSC distribution in colon cancer liver metastases. 
Following systemic RANTES-NIS-MSC injection, strong NIS-specific immunreactivity was detected 
confined to metastatic tissue (a), whereas normal liver tissue did not show NIS-specific 
immunostaining. No NIS-specific immunreactivity was detected following systemic injection of WT-
MSCs (b). SV40 large T Ag staining demonstrated the presence of RANTES-NIS-MSC (c) and WT-
MSC (d) in hepatic colon cancer metastases. Immunofluorescence analyses confirmed the co-
localisation of RANTES promoter-mediated NIS expression with MSC-specific SV40 large T Ag-
specific staining (e–g). Non-target organs including lung and kidney were negative for NIS-specific 
immunostaining (h, j) as well as MSC-specific SV40 large T Ag-specific staining (i, k) in colon cancer 
liver metastases-bearing mice following treatment with RANTES-NIS-MSC. 
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Analysis of NIS mRNA expression  
As a final validation of RANTES-induced transgene expression, NIS mRNA expression levels 
from whole metastatic liver tissue and non-target organs were analyzed by quantitative real-
time PCR using NIS-specific oligonucleotide primers. Metastatic livers from mice treated with 
RANTES-NIS-MSCs revealed a 7.6-fold increased level of NIS mRNA expression as 
compared to metastatic livers from mice treated with WT-MSCs. As expected, additional 
treatment with the competitive NIS inhibitor perchlorate (NaClO4) had no influence on NIS 
mRNA expression in metastases-bearing mice injected with RANTES-NIS-MSC (7.4-fold 
increase). In contrast, non-target organs like lung or kidney showed no NIS mRNA 
expression in RANTES-NIS-MSC- or WT-MSC-treated mice (Fig. 4). 
 
 
Figure 4 Analysis of NIS mRNA expression levels. Quantitative real time PCR revealed only 
background levels of NIS mRNA expression in liver metastases of mice injected with WT-MSC, 
whereas significant levels of NIS mRNA expression were detected in the livers of mice harbouring 
colon cancer liver metastases after application of RANTES-NIS-MSC injections (7.6-fold) and in mice 
additionally treated with the competitive NIS inhibitor perchlorate (NaClO4) (7.4-fold). In non-target 
organs including lung and kidney no NIS mRNA expression was seen after injection of RANTES-NIS-
MSC or WT-MSC. 
 
 
131I therapy study 
The therapeutic effect of 131I was assessed in mice carrying colon cancer liver metastases 
using the therapy regime optimized in previous studies. The protocol is based on three 
cycles of eMSC injections followed by 131I as outlined in Materials and Methods. After 
systemic injection of RANTES-NIS-MSC followed by 131I injection a significantly improved 
survival of up to 14 days was observed as compared to control groups (Fig. 5a).  
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Growth of metastases was monitored by MRI starting before the first 131I application after 
three injections of eMSCs (10 Days after intrasplenic tumor cell injection) when the tumor 
load in the liver was moderate (approximately 40%) (Fig. 5b). Over time, an exponential 
tumor growth was seen in the control groups (RANTES-NIS-MSC + NaCl or WT-MSC + 131I) 
(Fig. 5d) as compared to the therapy group (RANTES-NIS-MSC + 131I) that showed a 
significantly reduced tumor growth (Fig. 5c). MRI images at day 19 showed a reduced 
hepatic tumor load of approximately 63% in the therapy group (RANTES-NIS-MSC + 131I) as 
compared to a tumor load of at least 80-90% in the control group (RANTES-NIS-MSC + 
NaCl), while mice of the control groups not even survived the last 131I or saline application, 
respectively. 
 
 
Figure 5 Therapeutic efficacy of 131I in hepatic colon cancer metastases-bearing mice after 
systemic application of RANTES-NIS-MSC. Mice harbouring hepatic colon cancer metastases 
received two rounds of repetitive RANTES-NIS-MSC or WT-MSC applications followed by 131I (55.5 
MBq) administration. 24 h thereafter two additional MSC injections were applied followed by a third 
injection of 131I. A further control group received saline instead of 131I. Therapeutic application of 131I 
after injection of RANTES-NIS-MSCs resulted in significantly improved survival as compared to the 
control groups (a). Monitoring of metastases growth showed 10 days after intrasplenic LS174t cell 
injection small metastases in the liver with a hepatic tumor load of approx. 40% (b). Within one week 
exponential tumor growth was observed in the control group (RANTES-NIS-MSC + NaCl, tumor load 
approx. 80-90%) (d) as compared to the therapy group (RANTES-NIS-MSC + 131I) (c), which revealed 
delayed metastases growth (tumor load approx. 63%) at  day 19 after intrasplenic tumor cell injection. 
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At the end of experiments, animals were sacrificed, and their organs removed and 
characterized by immunofluorescence analysis for cellular proliferation (Ki67, green) and 
blood vessel density (CD31, red) markers. The results showed striking differences between 
therapy and control groups (Fig. 6a – c). Mice treated with RANTES-NIS-MSCs followed by 
131I showed decreased proliferation (Ki76: 23.3 % ± 2.5%) and blood vessel density (CD31: 
3.1% ± 0.2%), whereas control mice treated with RANTES-NIS-MSC followed by NaCl or 
treated with WT-MSCs followed by 131I revealed high blood vessel density (RANTES-NIS-
MSC + NaCl: CD31: 6.6% ± 0.7%; WT-MSC + 131I: CD31: 7.8% ± 0.8%) and high levels of 
proliferation (RANTES-NIS-MSC + NaCl: Ki67: 73.8% ± 6.9%; WT-MSC + 131I: Ki67: 76.5% ± 
6,7%) (Fig.6d, e).  
 
 
Figure 6 Ex vivo analyses of therapeutic effect. Immunofluorescence analyses of liver metastases 
using a Ki67-specific antibody (green, labelling proliferating cells) and an antibody against CD31 (red, 
labelling blood vessels) showed striking difference in tumor cell proliferation and blood vessel density 
in metastases of mice treated with RANTES-NIS-MSCs and 131I, (a), which was significantly reduced 
(Ki67: 23.3 % ± 2.5%; CD31: 3.1% ± 0.2% (d, e)) as compared to the control groups of mice treated 
with RANTES-NIS-MSC and saline (b) (Ki67: 73.8% ± 6.9%, CD31: 6.6% ± 0.7% (d, e)) or WT-MSC 
and 131I (c) (Ki67: 76.5% ± 6,7%, CD31: 7.8% ± 0.8% (d, e). Slides were counterstained with Hoechst 
nuclear stain. Magnification x200. 
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5.6 Discussion 
 
Colorectal cancer with advanced hepatic metastatic disease represents a major clinical 
problem. Despite advances in chemotherapy regimens, the only potential cure for patients 
presenting with colon cancer liver metastases remains surgical resection. At present, five-
year survival rates following liver resection still range between 25% - 40% compared to 0% - 
5% for non-operated patients, demonstrating the need for expanded therapeutic protocols 
(Siegel et al. 2013). 
Gene therapy represents an emerging therapy modality in the general treatment of cancer. It 
is based on the selective introduction of a diverse array of potential therapy genes within 
different tumor environments using various vehicles (Tang et al. 2010). In the present study, 
an emerging gene therapy approach was used in which the therapy gene was expressed in 
the context of eMSC-based protocols. eMSCs are excellent gene delivery vehicles based in 
part on their relative ease of engineering and expansion in vitro, while retaining their 
multilineage potential. Importantly, they also show a remarkable natural tropism for solid 
tumors (Dwyer and Kerin 2010; Dwyer et al. 2010; Tang et al. 2010). An array of therapy 
proteins have already been demonstrated to be successfully delivered to tumor environments 
using eMSC, including interferon-gamma, TRAIL ligands, IL-12, the chemokine CX3CL1, as 
well as various suicide genes (Deng et al. 2014; Gao et al. 2010; Kim et al. 2008). Recent 
studies have also shown that adoptively applied MSC can also efficiently home to tumor 
metastases opening the door to the potential use of eMSC for treatment of metastatic 
disease (Chen et al. 2008; Shinagawa et al. 2013; Su et al. 2013; Zhao et al. 2012).  
In one recent study, the authors used an IL-12-based eMSC approach that showed, in 
experimental models of melanoma, breast and hepatoma tumors, reduced progression of 
metastases at midstage of development, and even regression at later stages following an 
extended course of i.v. immunotherapy using IL-12 gene-engineered MSCs (Chen et al. 
2008). 
In addition to MSCs, related progenitor cells have also shown efficacy as therapy vehicles. In 
a model of metastatic breast cancer, Aboody et al. showed that human neural stem cells 
(NSC) can also target tumor metastases in multiple organs including liver, lymph nodes, and 
lung. The NSCs were engineered to constitutively secrete the suicide gene carboxylesterase 
(eNSC-rCE). This suicide gene encodes an enzyme that alters the CPT-11 prodrug into SN-
38, a potential topoisomerase I inhibitor. The final result is that high doses of the therapy 
drug are generated only where carboxylesterase is expressed. Systemic administration of 
tumor-bearing mice with eNSC-rCE cells, in concert with CPT-11 treatment, resulted in 
reduced metastastic tumor burden in lung and lymph nodes (Zhao et al. 2012). 
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The down side of gene therapy using traditional suicide genes is that even though they act 
through bystander killing, their effects are limited to the cells most proximal to the cells 
expressing the gene. In contrast, NIS-targeted radioiodine therapy is associated with a 
higher degree of bystander killing effect that results from 1) the crossfire effect of the β-
emitter 131I and 2) the radiation-induced biological bystander effect (Hingorani et al. 2007). 
This therapy concept has been effectively used for the treatment of differentiated thyroid 
cancer for almost 70 years and still represents one of the most effective systemic anticancer 
radiotherapies available to the clinician today. 
The application of the NIS gene as a combined imaging/therapy gene has been an area of 
expanded research in various tumor settings over the past few years. The ability to non-
invasively monitor the biodistribution of NIS expression after local and - even more important 
- systemic gene delivery provides an essential extension to the clinical setting. NIS itself is 
nontoxic; it is seen as “self” by the immune system, thus limiting potential immunogenicity; 
and a large numbers of NIS-compatible radioactive tracers are available including 123I for 
scintigraphy/SPECT, and 124I- and 18F-TFB for PET imaging (Jauregui-Osoro et al. 2010). 
Finally, NIS transgene expression allows the delivery of a robust therapeutic effect through 
131I or 188Re application application (Dwyer et al. 2005a; Dwyer et al. 2006; Dwyer et al. 2011; 
Herve et al. 2008; Kakinuma et al. 2003; Knoop et al. 2013; Peerlinck et al. 2009; Willhauck 
et al. 2007b; Willhauck et al. 2008c). The flexibility of this approach has been demonstrated 
more recently, in studies using oncolytic viruses and non-viral nanoparticles equipped with 
the NIS gene in order to facilitate non-invasive in vivo vector imaging as well as 131I-based 
radiotherapy after systemic application. We recently demonstrated tumor-selective 
radioiodine uptake and therapeutic efficacy of radiovirotherapy after systemic delivery of the 
NIS gene using a dendrimer-coated replication-selective adenovirus (Grunwald et al. 2013b; 
2013c). To optimize adenovirus shielding and targeting, we physically coated replication-
selective adenoviruses carrying the human NIS gene with a conjugate consisting of cationic 
poly(amidoamine) (PAMAM) dendrimer with or without an attached  targeting ligand,  the 
peptidic, epidermal growth factor receptor (EGFR)-specific ligand GE11. Systemic injection 
resulted in reduction of adenovirus liver pooling and decreased hepatotoxicity as well as 
increased transduction efficiency in peripheral hepatocellular xenograft tumors. Gamma 
camera imaging showed significantly higher levels of tumor-specific iodide accumulation 
resulting in a significantly enhanced oncolytic effect, which was further increased by 
therapeutic radioiodine treatment. (Grunwald et al. 2013b; 2013c). In an additional study by 
our group, nanoparticles based on linear polyethylenimine (LPEI) shielded by polyethylene 
glycol (PEG) and coupled with the EGFR-specific ligand GE11 was used to target a NIS-
expressing plasmid to hepatocellular Huh7 xenograft model in nude mice resulting in a 
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significant tumoral iodide uptake after systemic injection and a significant delay in tumor 
growth after therapeutic application of 131I (Klutz et al. 2011a). 
In previous studies we demonstrated proof of concept of systemic NIS gene delivery using 
MSCs as delivery vehicles using subcutaneous xenograft mouse models (Knoop et al. 2011; 
Knoop et al. 2013). Systemic application of eMSCs expressing NIS under the control of the 
tumor stroma-specific RANTES promoter (RANTES-NIS-MSC) led to a significant radioiodide 
accumulation in a subcutaneous hepatocellular Huh7 xenograft model in nude mice resulting 
in a delay of tumor growth and improved survival by therapeutic 131I application (Knoop et al. 
2013). However, while therapeutic efficacy has been demonstrated in subcutaneous solid 
tumor models using MSCs engineered to express NIS using the RANTES promoter, its 
potential efficacy in the treatment of tumor metastases represents a clinically important open 
issue. In the current study a liver metastasis model of colon cancer was used to analyze the 
biodistribution of MSC recruitment and NIS-mediated radioiodine accumulation.  
By 123I gamma-camera or 124I PET imaging NIS-eMSCs were shown to specifically home to 
liver metastases, and by extrapolation, induce RANTES promoter-driven NIS transgene 
expression, resulting in a tumor-selective radioiodine accumulation of up to 12% ID/g and a 
biological half-life of approx. 3 h. While 123I scintigraphic imaging showed a diffusely elevated 
radioiodine uptake in the hepatic area of mice carrying disseminated liver metastases, 124I 
small animal whole body PET imaging allowed a more detailed three-dimensional analysis of 
NIS-mediated radioiodine accumulation with higher resolution showing iodide uptake 
confined to metastatic nodules. Ex vivo analysis showed enhanced and NIS-specific iodine 
uptake in the liver of colon cancer metastases-bearing mice after treatment with NIS-eMSCs. 
This was further validated by immunohistological and quantitative PCR analyses. 
Immunohistology demonstrated strong immunoreactivity strictly confined to metastatic tissue 
without NIS and SV40 large T Ag expression in normal liver tissue or non-target organs. No 
metastatic spread was seen outside the liver, which was also reflected in negative tissue 
radioiodine uptake studies.  
In the therapy studies a significant reduction of tumor growth was observed associated with a 
significantly extended life span which is highly significant considering the aggressive growth 
of tumor metastases in this model. Hepatic tumor load as monitored in vivo by MRI showed a 
tumor load of approx. 40% prior to the first 131I application. Tumor growth increased 
dramatically to at least 80% in the control groups as compared to only 63% in the therapy 
group. These findings correlate with markedly reduced proliferation and blood vessel density 
in the tumors of the therapy group as measured by immunofluorescence analysis.  
In contrast to our study, many of previously published studies on gene therapy of metastatic 
disease analyzed therapeutic efficacy by ex vivo analyses. Zischek et al. showed reduced 
level of metastases in a pancreatic carcinoma mouse model a by ex vivo analyses after 
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treatment with MSCs expressing the HSV-TK suicide gene  However, the authors could not 
determine if this was due to direct effects on the primary tumor (leading to reduced 
production of metastases) or direct targeting of metastatic disease (Zischek et al. 2009). This 
study relied on ex vivo analysis of tumor growth. With the translation from animal to human 
studies in mind, in our current study we used contrast enhanced MRI to monitor the growth of 
hepatic colon cancer metastases over time in vivo. The contrast between tumor and normal 
tissue was enhanced by a liver-specific contrast agent (Primovist®), which allowed an 
optimal evaluation of treatment effects in hepatic metastases. MRI is emerging as a powerful 
method to investigate the potential effects of treatment approaches in mice. A study of 
Lavilla-Alonso et al. describes an optimized MRI protocol for analyzing the antitumor effects 
of an intrasplenically administered oncolytic adenovirus therapy, which resulted in reducing 
visceral tumor load and development of liver metastases (Lavilla-Alonso et al. 2011). 
In conclusion, in the current study we were able to translate our previous promising findings 
of MSC-mediated systemic NIS gene delivery in subcutaneous liver cancer xenografts into a 
clinically more relevant mouse model of show in a hepatic colon cancer metastases. Non-
invasive 123I gamma camera and 124I PET imaging demonstrated remarkable tumor selectivity 
of MSC recruitment and NIS expression driven by the tumor stroma-specific RANTES/CCL5 
promoter after systemic MSC application. The tumor stroma-targeted iodide uptake confined 
to liver metastases was strong enough for a significant reduction of metastases growth 
monitored in vivo by MRI resulting in in significantly improved survival. These data therefore 
convincingly demonstrate the enormous potential of MSC-mediated NIS gene radionuclide 
therapy in metastatic cancer. 
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6 Summary 
 
The tumor homing property of mesenchymal stem cells (MSC) has led to their use as 
delivery vehicles for reporter and therapeutic genes.  The sodium iodide symporter (NIS) 
represents one of the oldest and most successful targets for molecular imaging and 
radionuclide therapy, as it provides the molecular basis for the diagnostic and therapeutic 
application of radioiodine that has been successfully used for more than 70 years in the 
treatment of thyroid cancer patients, and represents the most effective form of systemic 
anticancer radiotherapy available to the clinicians today. Its theranostic properties allow non-
invasive imaging of functional NIS expression by 123I-scintigraphy or 124I-PET imaging, as well 
as robust therapeutic effects by treatment with 131I or 188Re. The application of NIS as 
reporter gene represents a novel mechanism for the evaluation of tumor selectivity, and 
general efficacy of the use of MSCs as gene delivery vehicles.  
In the first part of this thesis, human bone marrow derived CD34- MSCs were stably 
transfected with a NIS-expressing plasmid in which NIS was driven by the unspecific 
cytomegalovirus (CMV) promoter (NIS-MSC). After in vitro characterization of NIS-MSCs, 
MSC-mediated NIS expression was analysed in vivo via 123I-scintigraphy and 124I-PET 
imaging. The therapeutic potential of 131I-based therapy was then evaluated. After 
establishment of a subcutaneous hepatocellular carcinoma (HCC) (Huh7) xenograft model in 
nude mice, NIS-MSCs were systemically injected and radioiodine biodistribution as well as 
tumor selectivity analysed using non-invasive imaging procedures. 123I-scintigraphy, 124I-PET 
imaging and ex vivo biodistribution analyses revealed active MSC recruitment into HCC 
xenografts as shown by tumor-selective iodide accumulation (9.5 % ID/g 123I, biological half-
life: 4 h) that was confirmed by ex vivo biodistribution studies, immunostaining and 
quantitative real-time PCR analyses. Finally, the use of NIS as therapeutic gene in HCC 
xenografts led to a pronounced delay in tumor growth after application of 131I which was 
associated with improved survival. These results convincingly show tumor-selective 
recruitment of MSCs in HCC xenografts that can be used for targeted delivery of NIS as 
reporter and therapy gene. 
The next goal of this study, we attempted to refine the tumor stroma selectivity of MSC-
mediated NIS expression. Upregulation of the chemokine CCL5 (RANTES) by MSCs within 
the tumor stroma in the process of tumor stroma recruitment of MSCs, and their 
differentiation into cancer associated fibroblasts, is thought to play an important role in 
cancer growth and metastases. Therefore, use of the RANTES/CCL5 promoter to drive NIS 
expression in genetically engineered MSCs should allow tumor stroma selectivity of NIS 
expression after MSC-mediated delivery. MSCs were stably transfected with a plasmid in 
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which NIS was driven by the RANTES/CCL5 promoter (RANTES-NIS-MSC). After systemic 
injection of RANTES-NIS-MSC in the same HCC xenograft mouse model that was used in 
the previous studies, 123I-scintigraphy revealed active MSC recruitment into the tumor stroma 
as well as CCL5 promoter activation as shown by tumor-selective NIS-mediated iodide 
accumulation (6.5% ID/g 123I, biological half-life: 3.7 h). The iodide uptake activity in the 
tumor was sufficient for a therapeutic effect with 131I demonstrating a significant delay of 
tumor growth and improved overall survival. In addition, the potential of 188Re, which is also 
transported by NIS, as an alternative diagnostic and therapeutic radionuclide was examined. 
In contrast to 131I, it offers the possibility of higher energy deposition in the tumor in a shorter 
period of time due to its shorter physical half-life and higher energy of beta particles. Due to 
the longer path length of beta particles of 10.4 mm as compared to 2.4 mm for 131I, also an 
enhanced crossfire effect is expected which could serve as an advantage in the context of 
MSC-mediated NIS gene delivery due to the scattered MSC distribution in the tumor stroma. 
Systemic application of RANTES-NIS-MSC in subcutaneous HCC tumor-bearing mice 
resulted in 188Re accumulation specifically in the tumor (7 % ID/g, biological half-life: 4.1 h). 
However, in direct comparison to 131I, the therapeutic effect of 188Re was similar after 
RANTES-NIS-MSC-mediated NIS gene delivery resulting in a marked delay in tumor growth 
and significantly improved survival over ten weeks after NIS-mediated radionuclide therapy, 
although the tumor-absorbed dose for 188Re was calculated to be three-times higher than for 
131I. Based on the survival data obtained for both radionuclides, it is possible that a maximal 
therapeutic effect was already achieved with 131I treatment. Therapeutic results showed a 
significant improvement over those we previously reported using the CMV promoter to drive 
NIS expression in the same model system where the mice lived only seven weeks after NIS 
mediated radioiodine therapy. In comparison to the first part of the thesis, these results 
demonstrate high tumor selectivity of MSC recruitment and NIS expression driven by the 
RANTES/CCL5 promoter after systemic MSC application. The resulting biologically targeted, 
tumor-selective radionuclide accumulation was high enough for a significant enhanced 
therapeutic effect of 131I and 188Re in a HCC xenograft model. 
In the next stage we established an orthotopic HCC xenograft model to study MSC 
recruitment and therapy in the context of normal tissue-tumor interplay. Human HCC cells 
were injected in the right liver lobe which resulted in a single orthotopic liver tumor. RANTES-
NIS-MSCs were systemically injected and MSC biodistribution and NIS expression analysed 
by in vivo imaging studies, followed by ex vivo radioiodine biodistribution studies as well as 
NIS expression analysis. 123I-scintigraphy, 124I-PET imaging and ex vivo studies 
demonstrated active MSC recruitment and RANTES promoter-driven NIS expression in the 
intrahepatic HCC xenograft model, while no NIS expression was seen in healthy liver tissue 
or in non-target organs. The iodide uptake activity in intrahepatic xenografts was higher than 
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in subcutaneous flank tumors, which may be due to an enhanced tumor stroma growth within 
the hepatic environment. The tumoral radioiodine uptake was also high enough for a 
therapeutic effect of 131I therapy resulting in an improved survival after systemic injection of 
RANTES-NIS-MSCs. The tumor homing capacity of the NIS expressing MSCs under the 
control of a tumor stroma specific promoter highlights their potential use for future clinical 
investigation and justifies investigation in more advanced tumor models.  
While therapeutic effects have been demonstrated in xenograft solid tumor models using 
RATNES-NIS-MSCs, its potential efficacy in treatment of tumor metastases represents a 
clinically important issue. Therefore, in the last part of the thesis a hepatic colon cancer 
metastases model was established. Colon cancer cells were injected into the spleen 
resulting in induction of multifocal liver metastases. After systemic injection of RANTES-NIS-
MSCs, imaging studies (123I-scintigraphy and 124I-PET) demonstrated specific MSC-homing 
to liver metastases as shown by enhanced iodide uptake activity in the liver, whereas healthy 
liver tissue and non-target organs did not reveal NIS-specific iodide uptake. Successful 
therapeutic radioiodine treatment resulted in an improved survival in hepatic colon cancer 
metastases-bearing mice after systemic injection of RANTES-NIS-MSCs. Growth of 
metastases was observed by magnetic resonance imaging (MRI) showing a significantly 
delay in tumor mass after therapeutic treatment (63 %) as compared to the control group 
revealing a tumor mass of 80% after the last of three 131I or NaCl application, respectively.  
In conclusion, the data of this thesis convincingly demonstrate the potential of genetically 
engineered MSCs as tumor-selective gene transfer vehicles for the theranostic NIS gene 
based on their tumor-specific homing after systemic injection in various tumor models 
including liver metastases models, which opens the exciting prospect of clinical application of 
targeted NIS-mediated radionuclide therapy of non-thyroidal cancers, even in metastatic 
disease. 
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57th Annual Meeting of the German Society of Endocrinology, Berlin, March 2014 
In vivo imaging of mesenchymal stem cell recruitment into the tumor stroma of hepatocellular 
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Guido Böning, Heidrun Zankl, Marcus Hacker, Burkhard Göke, Ernst Wagner, Peter J 
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